The distribution of tangles, plaques and related immune
aging and Alzheimer's disease

Neurobiology of Aging

12, 295-312

DOI: 10.1016/0197-4580(91)90006-6

Citation Report

#	Article	IF	Citations
2	Association between vascular basement membrane components and the lesions of Alzheimer's disease. Journal of Neuroscience Research, 1991, 30, 673-681.	2.9	98
3	Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology, 1992, 42, 631-631.	1.1	2,379
4	Evidence for Early Vulnerability of the Medial and Inferior Aspects of the Temporal Lobe in an 82-Year-Old Patient With Preclinical Signs of Dementia. Archives of Neurology, 1992, 49, 946.	4.5	121
5	The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neuroscience Research, 1992, 15, 6-31.	1.9	303
6	Distribution of neurofibrillary tangles and senile plaques in the cerebral cortex in postencephalitic parkinsonism. Neuroscience Letters, 1992, 139, 10-14.	2.1	42
7	Î² A4 amyloid protein and its precursor in Alzheimer's disease. , 1992, 56, 97-117.		32
8	Presence of abnormally phosphorylated Tau proteins in the entorhinal cortex of aged non-demented subjects. Neuroscience Letters, 1992, 144, 143-146.	2.1	43
9	Olfactory bulb lesions in alzheimer's disease. Neurobiology of Aging, 1992, 13, 469-473.	3.1	70
10	Down's syndrome: occurrence of ALZ-50 reactive neurons and the formation of senile plaques. Journal of the Neurological Sciences, 1992, 109, 77-82.	0.6	19
11	Progressive transformation of the cytoskeleton associated with normal aging and Alzheimer's disease. Brain Research, 1992, 594, 273-278.	2.2	102
12	Allocortical neurofibrillary changes in progressive supranuclear palsy. Acta Neuropathologica, 1992, 84, 478-483.	7.7	69
13	Mapping of neurofibrillary degeneration in Alzheimer's disease: evaluation of heterogeneity using the quantification of abnormal tau proteins. Acta Neuropathologica, 1992, 85, 48-54.	7.7	51
14	Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Annals of Neurology, 1992, 32, 625-632.	5.3	219
15	Synapse loss in the temporal lobe in Alzheimer's disease. Annals of Neurology, 1993, 33, 190-199.	5.3	227
16	Dementia in Parkinson's disease: Biochemical evidence for cortical involvement using the immunodetection of abnormal tau proteins. Annals of Neurology, 1993, 33, 445-450.	5.3	60
17	Quantitative assessment of synaptic density in the entorhinal cortex in Alzheimer's disease. Annals of Neurology, 1993, 34, 356-361.	5.3	80
18	Pathological markers associated with normal aging and dementia in the elderly. Annals of Neurology, 1993, 34, 566-573.	5.3	166
19	Evidence that transmitter-containing dystrophic neurites precede paired helical filament and Alz-50 formation within senile plaques in the amygdala of nondemented elderly and patients with Alzheimer's disease. Journal of Comparative Neurology, 1993, 334, 176-191.	1.6	52

#	Article	IF	Citations
20	Quantitative immunohistochemical analysis of the distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of nonagenarians and centenarians. Acta Neuropathologica, 1993, 85, 602-610.	7.7	61
21	Drastic reduction of the zinc- and magnesium-stimulated protein tyrosine kinase activities in Alzheimer's disease hippocampus. FEBS Letters, 1993, 328, 6-8.	2.8	13
22	Organization and quantitative analysis of kainate receptor subunit GluR5-7 immunoreactivity in monkey hippocampus. Brain Research, 1993, 624, 347-353.	2.2	50
23	Immunocytochemical distribution of peptidergic and cholinergic fibers in the human amygdala: their depletion in Alzheimer's disease and morphologic alteration in non-demented elderly with numerous senile plaques. Brain Research, 1993, 625, 125-138.	2.2	43
24	Towards an improved survival of rat brain neurons in culture by cerebrospinal fluid of patients with senile dementia of Alzheimer's type. Brain Research, 1993, 610, 8-15.	2.2	10
25	The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease. Brain Research, 1993, 629, 189-198.	2.2	76
26	Evidence that transmitter-containing dystrophic neurites precede those containing paired helical filaments within senile plaques in the entorhinal cortex of nondemented elderly and Alzheimer's disease patients. Brain Research, 1993, 619, 55-68.	2.2	32
27	Î±2-macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease. Neurobiology of Aging, 1993, 14, 233-237.	3.1	104
28	The relationship between tangle and plaque formation during healthy aging and mild dementia. Neurobiology of Aging, 1993, 14, 661-663.	3.1	26
29	Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes. Neuroscience Letters, 1993, 153, 131-135.	2.1	132
30	Neuroanatomical connections and specific regional vulnerability in Alzheimer's disease. Neurobiology of Aging, 1993, 14, 45-47.	3.1	27
31	Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neuroscience Letters, 1993, 162, 179-182.	2.1	297
32	Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiology of Aging, 1993, 14, 589-596.	3.1	65
33	Axonal loss from the olfactory tracts in alzheimer's disease. Neurobiology of Aging, 1993, 14, 353-357.	3.1	62
34	Two neurotropic viruses, herpes simplex virus type 1 and mouse hepatitis virus, spread along different neural pathways from the main olfactory bulb. Neuroscience, 1993, 57, 1007-1025.	2.3	128
35	Reliability and Usefulness of a New Immunochemical Assay for Alzheimer's Disease. Archives of Neurology, 1993, 50, 57-63.	4.5	1
36	Neuropathological Indexes of Alzheimer's Disease in Demented and Nondemented Persons Aged 80 Years and Older. Archives of Neurology, 1993, 50, 349-358.	4.5	247
37	Increased Levels of Truncated Nerve Growth Factor Receptor in Urine of Mildly Demented Patients With Alzheimer's Disease. Archives of Neurology, 1993, 50, 1054-1058.	4.5	19

#	Article	IF	Citations
38	Structural correlates and cellular mechanisms in entorhinalâ€"hippocampal dysfunction. Hippocampus, 1993, 3, 293-301.	1.9	10
39	Recent research on the causes of Alzheimer's disease. Proceedings of the Nutrition Society, 1993, 52, 255-262.	1.0	4
41	Entorhinalâ€"hippocampal interaction in mnestic disorders. Hippocampus, 1993, 3, 239-246.	1.9	65
42	Differential Diagnosis of Alzheimerâ€™s Disease. Clinics in Geriatric Medicine, 1994, 10, 257-276.	2.6	29
43	Dementia in the Oldest-Old:Quantitative Analysis of 12 Cases from a Psychiatric Hospital. Dementia and Geriatric Cognitive Disorders, 1994, 5, 348-356.	1.5	14
44	Basal forebrain lesions in monkeys disrupt attention but not learning and memory [published erratum appears in J Neurosci 1995 Mar;15(3): following table of contents]. Journal of Neuroscience, 1994, 14, 167-186.	3.6	480
45	NMDA receptors: the first decade. Expert Opinion on Investigational Drugs, 1994, 3, 341-354.	4.1	5
46	Computed detection and quantitative morphometry of Alzheimer senile plaques. Journal of Neuroscience Methods, 1994, 52, 175-189.	2.5	11
47	Cortical and striatal neurone number in Huntington's disease. Acta Neuropathologica, 1994, 88, 320-333.	7.7	155
48	Alzheimer's disease with asymmetric atrophy of the cerebral hemispheres: morphometric analysis of four cases. Acta Neuropathologica, 1994, 88, 440-447.	7.7	32
49	Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathologica, 1994, 87, 456-468.	7.7	100
50	Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathologica, 1994, 87, 469-480.	7.7	290
51	Senile plaques in temporal lobe epilepsy. Acta Neuropathologica, 1994, 87, 504-510.	7.7	153
52	Senile plaques do not progressively accumulate with normal aging. Acta Neuropathologica, 1994, 87, 520-525.	7.7	61
53	Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathologica, 1994, 87, 174-186.	7.7	30
54	Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: a rare subtype in very old subjects. Acta Neuropathologica, 1994, 88, 565-570.	7.7	97
55	Cytological demonstration of features of Alzheimer's disease using brain smear technique. Diagnostic Cytopathology, 1994, 10, 320-325.	1.0	3
56	Alzheimer's disease: Recent advances in molecular pathology and genetics. International Journal of Geriatric Psychiatry, 1994, 9, 431-444.	2.7	9

#	Article	IF	Citations
57	APOE is a major susceptibility gene for Alzheimer's disease. Current Opinion in Biotechnology, 1994, 5, 663-667.	6.6	97
58	Regional Distribution of Neurofibrillary Tangles and Senile Plaques in the Cerebral Cortex of Elderly Patients: A Quantitative Evaluation of a One-Year Autopsy Population from a Geriatric Hospital. Cerebral Cortex, 1994, 4, 138-150.	2.9	254
59	Microtubule-associated protein MAP1B showing a fetal phosphorylation pattern is present in sites of neurofibrillary degeneration in brains of Alzheimer's disease patients. Molecular Brain Research, 1994, 26, 113-122.	2.3	86
60	Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiology of Aging, 1994, 15, 355-356.	3.1	157
61	Studying the Alzheimer's disease brain: Insights, puzzles, and opportunities. Neurobiology of Aging, 1994, 15, 79-83.	3.1	5
62	Î²-Amyloid (AÎ²) deposition in elderly non-demented patients and patients with Alzheimer's disease. Neuroscience Letters, 1994, 178, 59-62.	2.1	19
63	Human striatum: the distribution of neurofibrillary tangles in Alzheimer's disease. Brain Research, 1994, 648, 327-331.	2.2	49
64	Terminin (Tp 63/60), a novel cell senescence-related protein, is present in the aging human hippocampus. Brain Research, 1994, 644, 188-196.	2.2	8
65	Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet, The, 1994, 344, 769-772.	13.7	1,142
66	Acetylcholinesterase provides deeper insights into Alzheimer's disease. Medical Hypotheses, 1994, 43, 21-30.	1.5	21
67	Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience, 1994, 62, 15-30.	2.3	350
68	Phosphoinositide metabolism, aging and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1994, 1225, 111-124.	3.8	25
69	Attentional disengagement deficit in nondemented elderly over 75 years of age. Aging, Neuropsychology, and Cognition, 1994, 1, 188-202.	1.3	51
70	Reverse genetics of the mouse central nervous system: Targeted genetic analysis of neuropeptide function and reverse genetic screens for genes involved in human neurodegenerative disease. Progress in Neurobiology, 1994, 42, 319-331.	5.7	3
71	Chapter 30 Functional integrity of neural systems related to memory in Alzheimer's disease. Progress in Brain Research, 1994, 100, 245-254.	1.4	5
72	Reduced Temporal Lobe Glucose Metabolism in Aging. Journal of Neuroimaging, 1995, 5, 178-182.	2.0	31
74	Aging, alzheimer's disease, and word recognition: A review of the recent literature. Advances in Psychology, 1995, , 220-246.	0.1	4
75	Morphometrical comparison of neurofibrillary tangles and senile plaques in Alzheimer's disease and the senile dementia of Alzheimer type. Neuropathology, 1995, 15, 21-26.	1.2	6

#	Article	IF	Citations
76	Microglial inter leukinâ€1Î± expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Neuropathology and Applied Neurobiology, 1995, 21, 290-301.	3.2	174
77	Reduction of Î²â€amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology, 1995, 38, 643-648.	5.3	673
78	Morphology and kainate-receptor immunoreactivity of identified neurons within the entorhinal cortex projecting to superior temporal sulcus in the cynomolgus monkey. Journal of Comparative Neurology, 1995, 357, 25-35.	1.6	16
79	Beta-Amyloid Deposition in the Medial Temporal Lobe in Elderly Non-Demented Brains and in Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 1995, 6, 121-125.	1.5	11
80	Alzheimer's diseaseâ€"new approaches to old problems. International Review of Psychiatry, 1995, 7, 419-435.	2.8	1
81	Odor identification as an early marker for Alzheimer's disease: Impact of lexical functioning and detection sensitivity. Journal of Clinical and Experimental Neuropsychology, 1995, 17, 793-803.	1.3	152
82	Cognitive Test Performance in Detecting, Staging, and Tracking Alzheimer's Disease. Archives of Neurology, 1995, 52, 1087-1099.	4.5	212
83	DNA Testing Detente?. Science, 1995, 268, 371-371.	12.6	0
84	The Morphologic and Neurochemical Basis of Dementia: Aging, Hierarchical Patterns of Lesion Distribution and Vulnerable Neuronal Phenotype. Reviews in the Neurosciences, 1995, 6, 97-124.	2.9	28
85	Regional Distribution of Neurofibrillary Tangles and Senile Plaques in the Cerebral Cortex of Very Old Patients. Archives of Neurology, 1995, 52, 1150-1159.	4.5	67
86	Unawareness of Smell Loss in Normal Aging and Alzheimer's Disease: Discrepancy between Self-Reported and Diagnosed Smell Sensitivity. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 1995, 50B, P187-P192.	3.9	202
87	Quantitative analysis of neuropathologic changes in the cerebral cortex of centenarians. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 577-592.	4.8	19
88	Cortical mapping of Alzheimer pathology in brains of aged non-demented subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 1035-1047.	4.8	23
89	Glial cytokines in Alzheimer's disease: Review and pathogenic implications. Human Pathology, 1995, 26, 816-823.	2.0	411
90	Alzheimer's Disease: Maladaptive Synaptoplasticity Hypothesis. Experimental Neurology, 1995, 4, 217-232.	1.7	29
91	Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. Journal of the Neurological Sciences, 1995, 131, 162-169.	0.6	205
92	Neuroanatomy of Alzheimer's disease: Hierarchical vulnerability and neural system compromise. Neurobiology of Aging, 1995, 16, 278-280.	3.1	276
93	Staging of alzheimer's disease-related neurofibrillary changes. Neurobiology of Aging, 1995, 16, 271-278.	3.1	1,943

#	Article	IF	Citations
94	Role of microglia in senile plaque formation. Neurobiology of Aging, 1995, 16, 797-804.	3.1	180
95	Neocortical Neurofibrillary Tangles Correlate With Dementia Severity in Alzheimer's Disease. Archives of Neurology, 1995, 52, 81-88.	4.5	456
96	Increased messenger RNA expression of the 695 and 751 amino acid isoforms of the Î²-amyloid protein precursor in the thalamus of 17-year-old cynomolgus (Macaca fascicularis) monkeys. Neuroscience, 1995, 65, 51-57.	2.3	15
97	Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology, 1995, 45, 1594-1601.	1.1	597
98	Stilboestrol exposure in utero and risk of pre-eclampsia. Lancet, The, 1995, 345, 265-266.	13.7	3
99	Hippocampal volume losses in minimally impaired elderly. Lancet, The, 1995, 345, 266.	13.7	98
101	APP transgenesis: Approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiology of Aging, 1996, 17, 153-171.	3.1	50
102	In Vivo Structural Studies of the Hippocampus in Normal Aging and in Incipient Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1996, 777, 1-13.	3.8	83
103	Functional Imaging Patterns in Alzheimer's Disease Relationships to Neurobiologya. Annals of the New York Academy of Sciences, 1996, 777, 30-36.	3.8	25
104	Dystrophic Neurite Formation Associated with Age-Related Î² Amyloid Deposition in the Neocortex: Clues to the Genesis of Neurofibrillary Pathology. Experimental Neurology, 1996, 141, 1-11.	4.1	78
105	A Comparison of Î²-Amyloid Deposition in the Medial Temporal Lobe in Sporadic Alzheimer's Disease, Down's Syndrome and Normal Elderly Brains. Experimental Neurology, 1996, 5, 35-41.	1.7	17
106	Comparative Investigation of Neurofibrillary Damage in the Temporal Lobe in Alzheimer's Disease, Down's Syndrome and Dementia Pugilistica. Experimental Neurology, 1996, 5, 259-264.	1.7	22
107	Neuropsychological features of early Alzheimer's disease: preclinical and clinical stages. Acta Neurologica Scandinavica, 1996, 94, 63-71.	2.1	85
108	Hippocampal Pathology Reflects Memory Deficit and Brain Imaging Measurements in Alzheimers Disease: Clinicopathologic Correlations Using Three Sets of Pathologic Diagnostic Criteria. Dementia and Geriatric Cognitive Disorders, 1996, 7, 76-81.	1.5	53
109	GERIATRIC BIOSCIENCE: Hippocampal and Neocortical Involvement in Normal Brain Aging and Dementia: Morphological and Neurochemical Profile of the Vulnerable Circuits. Journal of the American Geriatrics Society, 1996, 44, 857-864.	2.6	19
110	Ageâ€Associated Memory Impairment and Alzheimer's Disease. Journal of the American Geriatrics Society, 1996, 44, 209-211.	2.6	11
111	Neuropathological Diagnosis of Dementia Using Silver Stains and Immunohistochemical Techniques. Journal of Histotechnology, 1996, 19, 235-240.	0.5	2
112	Chapter 7 Neuronal Aging and Alzheimer's Disease. Advances in Cell Aging and Gerontology, 1996, 1, 157-168.	0.1	2

#	Article	IF	Citations
113	Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimerâ€™s Disease. Journal of Neuroscience, 1996, 16, 4491-4500.	3.6	1,570
114	Perceptual priming in Alzheimer's and Parkinson's diseases. Neuropsychologia, 1996, 34, 449-457.	1.6	53
115	Diagnostic accuracy of alzheimerâ€™s disease: A neuropathological study. Acta Neuropathologica, 1996, 91, 185-193.	7.7	105
116	Early-onset dementias: clinical, neuropathological and genetic characteristics. Acta Neuropathologica, 1996, 91, 451-465.	7.7	21
117	Pattern of brain destruction in Parkinson's and Alzheimer's diseases. Journal of Neural Transmission, 1996, 103, 455-490.	2.8	309
118	Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. European Archives of Psychiatry and Clinical Neuroscience, 1996, 246, 137-146.	3.2	120
119	Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. Neuropathology and Applied Neurobiology, 1996, 22, 334-341.	3.2	43
120	Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Brain Research, 1996, 741, 284-293.	2.2	41
121	cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe65 protein. Human Molecular Genetics, 1996, 5, 1589-1598.	2.9	109
122	Obtaining consent for autopsy in dementia research: The Memory and Aging Project experience. , 1996, 11, 2-6.		1
123	Associations of Status and Change Measures of Neuropsychological Function With Pathologic Changes in Elderly, Originally Nondemented Subjects. Archives of Neurology, 1996, 53, 82-87.	4.5	25
124	Prospective neuropsychological assessment of nondemented patients with biopsy proven senile plaques. Neurology, 1996, 46, 425-429.	1.1	29
125	Olfactory Dysfunction for Pyridine and Dementia Progression in Alzheimer Disease. Archives of Neurology, 1997, 54, 993-998.	4.5	45
126	The Ratio of Mesial to Neocortical Temporal Lobe Blood Flow as a Predictor of Dementia. Journal of the American Geriatrics Society, 1997, 45, 329-333.	2.6	11
127	Chapter 3 Structural Changes in the Aged Brain. Advances in Cell Aging and Gerontology, 1997, , 51-76.	0.1	0
128	A Novel Metalloprotease in Rat Brain Cleaves the Amyloid Precursor Protein of Alzheimer's Disease Generating Amyloidogenic Fragments. Biochemistry, 1997, 36, 156-163.	2.5	23
129	Alzheimer-type of pathological changes in Chinese. Journal of the Neurological Sciences, 1997, 145, 97-103.	0.6	7
130	Life and Death of Neurons in the Aging Brain. Science, 1997, 278, 412-419.	12.6	1,226

#	Article	IF	Citations
131	Estrogen and the Treatment of Alzheimerâ€™s Disease. American Journal of Medicine, 1997, 103, 36S-45S.	1.5	40
132	Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Research Reviews, 1997, 25, 217-245.	9.0	163
133	Olfactory event-related potentials: older males demonstrate the greatest deficits. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1997, 104, 351-358.	2.0	70
134	Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiology of Aging, 1997, 18, 1-11.	3.1	830
135	Specific Hippocampal Volume Reductions in Individuals at Risk for Alzheimerâ€™s Disease. Neurobiology of Aging, 1997, 18, 131-138.	3.1	376
137	Neuropathological Staging of Alzheimer-Related Lesions: The Challenge of Establishing Relations to Age. Neurobiology of Aging, 1997, 18, 369-375.	3.1	12
138	The Value of Cross Sectional Neuroanatomical Studies as a Conceptual Framework for Prospective Clinicopathological Studies. Neurobiology of Aging, 1997, 18, 382-386.	3.1	10
139	The Challenge of Characterizing Normal Brain Aging in Relation to Alzheimerâ€™s Disease. Neurobiology of Aging, 1997, 18, 388-389.	3.1	12
140	Comparison of Neuropathologic Criteria for the Diagnosis of Alzheimerâ€™s Disease. Neurobiology of Aging, 1997, 18, S99-S105.	3.1	88
141	Neuropathological Criteria for the Diagnosis of Alzheimerâ€™s Disease. Neurobiology of Aging, 1997, 18, S13-S19.	3.1	70
142	Neuropathological Diagnosis of Alzheimerâ€™s Disease: A Perspective from Longitudinal Clinicopathological Studies. Neurobiology of Aging, 1997, 18, S21-S26.	3.1	142
143	Proposals for Re-evaluation of Current Autopsy Criteria for the Diagnosis of Alzheimerâ€™s Disease. Neurobiology of Aging, 1997, 18, S55-S65.	3.1	21
144	Diagnostic Criteria for Alzheimerâ€™s Disease. Neurobiology of Aging, 1997, 18, S67-S70.	3.1	36
145	Proposal to Revise the Morphologic Criteria for the Diagnosis of Alzheimerâ€™s Disease. Neurobiology of Aging, 1997, 18, S81-S84.	3.1	2
146	Preserved Number of Entorhinal Cortex Layer II Neurons in Aged Macaque Monkeys. Neurobiology of Aging, 1997, 18, 549-553.	3.1	114
147	Choline acetyltransferase mRNA expression in the striatal neurons of patients with Alzheimer's disease. Neuroscience Letters, 1997, 225, 169-172.	2.1	24
148	A Cellular Mechanism for the Neuronal Changes Underlying Alzheimerâ€˜s Disease. Neuroscience, 1997, 78, 629-639.	2.3	32
149	AÎ² Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse. Journal of Neuroscience, 1997, 17, 7053-7059.	3.6	490

#	Article	IF	Citations
150	Cerebromicrovascular Pathology in Alzheimerâ€™s Disease Compared to Normal Aging. Gerontology, 1997, 43, 26-43.	2.8	79
151	Involvement of Neuronal Anion Exchange Proteins in Cell Death in Alzheimer's Disease. Gerontology, 1997, 43, 67-78.	2.8	13
153	Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. Neuropathology and Applied Neurobiology, 1997, 23, 483-491.	3.2	34
154	The progression of Î²-amyloid deposition in the frontal cortex of the aged canine. Brain Research, 1997, 774, 35-43.	2.2	87
155	Metallothioneins in Brainâ€"The Role in Physiology and Pathology. Toxicology and Applied Pharmacology, 1997, 142, 229-242.	2.8	182
156	Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease?. Acta Neuropathologica, 1997, 93, 146-153.	7.7	68
157	Quantitative analysis of tau protein-immunoreactive accumulations and Î² amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus. Acta Neuropathologica, 1997, 94, 131-139.	7.7	66
158	Differential pattern of Î²-amyloid, amyloid precursor protein and apolipoprotein E expression in cortical senile plaques. Acta Neuropathologica, 1997, 94, 255-265.	7.7	19
159	Lack of correlation between plaque burden and cognition in the aged monkey. Acta Neuropathologica, 1997, 94, 471-478.	7.7	86
160	Age Effects on Central Nervous System Activity Reflected in the Olfactory Event-Related Potential: Evidence for Decline in Middle Agea. Annals of the New York Academy of Sciences, 1998, 855, 598-607.	3.8	19
161	Odor Memory in Normal Aging and Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1998, 855, 686-693.	3.8	67
162	Apolipoprotein E Status is Associated with Odor Identification Deficits in Nondemented Older Personsa. Annals of the New York Academy of Sciences, 1998, 855, 744-750.	3.8	112
163	Sympathetic neurite outgrowth is greater on plaque-poor vs. plaque-rich regions of Alzheimer's disease cryostat sections. Brain Research, 1998, 787, 49-58.	2.2	7
164	Selective vulnerability of neocortical association areas in Alzheimer's disease. Microscopy Research and Technique, 1998, 43, 16-23.	2.2	28
165	Pitfalls in the quantitative estimation of Î²-amyloid immunoreactivity in human brain tissue. Histochemistry and Cell Biology, 1998, 110, 439-445.	1.7	14
166	Cognitive impairment in Parkinson's disease. European Journal of Neurology, 1998, 5, 431-441.	3.3	24
167	Visual-discrimination learning ability and Î²-amyloid accumulation in the dog. Neurobiology of Aging, 1998, 19, 415-425.	3.1	160
168	Progression of neurofibrillary changes and PHF-Ï„ in end-stage Alzheimerâ€™s disease is different from plaque and cortical microglial pathology. Neurobiology of Aging, 1998, 19, 517-525.	3.1	67

#	Article	IF	Citations
169	Cortical distribution of neurofibrillary tangles in Alzheimer's disease matches the pattern of neurons that retain their capacity of plastic remodelling in the adult brain. Neuroscience, 1998, 83, 991-1002.	2.3	122
170	NEUROIMAGING OF THE AGING BRAIN. Neurologic Clinics, 1998, 16, 581-598.	1.8	34
171	The neurotoxicity of amyloid beta protein in aged primates. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 1-9.	3.0	57
172	Memory Performances in Young, Elderly, and Very Old Healthy Individuals versus Patients with Alzheimer's Disease: Evidence for Discontinuity Between Normal and Pathological Aging. Journal of Clinical and Experimental Neuropsychology, 1998, 20, 14-29.	1.3	62
173	Increased Peroxidation and Reduced Antioxidant Enzyme Activity in Alzheimer's Disease. Experimental Neurology, 1998, 150, 40-44.	4.1	432
174	Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis. Experimental Neurology, 1998, 150, 296-304.	4.1	186
175	Density of Choline Acetyltransferase-Immunoreactive Terminals in the Rat Dentate Gyrus after Entorhinal Cortex Lesions: A Quantitative Light Microscope Study. Experimental Neurology, 1998, 152, 50-63.	4.1	13
176	Disseminated Corticolimbic Neuronal Degeneration Induced in Rat Brain by MK-801: Potential Relevance to Alzheimer's Disease. Neurobiology of Disease, 1998, 5, 305-322.	4.4	83
177	Category-Specific Semantic Deficits in Focal and Widespread Brain Damage: A Computational Account. Journal of Cognitive Neuroscience, 1998, 10, 77-94.	2.3	344
178	Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer Disease. Archives of Neurology, 1998, 55, 326.	4.5	630
179	Reevaluating the Role of Vascular Changes in the Differential Diagnosis of Alzheimerâ€™s Disease and Vascular Dementia. European Neurology, 1998, 40, 121-129.	1.4	41
180	Neurofibrillary Tangles and Alzheimerâ€™s Disease. European Neurology, 1998, 40, 130-140.	1.4	138
181	Pathologic Correlates of Apraxia in Alzheimer Disease. Archives of Neurology, 1998, 55, 689.	4.5	53
182	Chapter 26 Reduced neuronal activity and reactivation in Alzheimer's disease. Progress in Brain Research, 1998, 117, 343-377.	1.4	59
183	A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: Implications for theories of executive functioning and cognitive aging. Journal of the International Neuropsychological Society, 1998, 4, 474-90.	1.8	503
184	Chapter 20 Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Progress in Brain Research, 1998, 117, 267-285.	1.4	119
185	Excitotoxic lesions centered on perirhinal cortex produce delay-dependent deficits in a test of spatial memory.. Behavioral Neuroscience, 1998, 112, 512-524.	1.2	94
186	Normal Aging and Alzheimer's Disease. , 1998, , 83-92.		2

#	Article	IF	Citations
187	Electrochemical Analysis of Protein Nitrotyrosine and Dityrosine in the Alzheimer Brain Indicates Region-Specific Accumulation. Journal of Neuroscience, 1998, 18, 8126-8132.	3.6	478
188	Neurochemical aspects of memory dysfunction in neurodegenerative disease. , 1998, , 87-99.		0
189	Drug treatment of cognitive impairment in neurodegenerative disease: rationale, current experience and expectations for the future. , 1998, , 349-361.		0
190	Regional Selective Neuronal Degeneration after Protein Phosphatase Inhibition in Hippocampal Slice Cultures: Evidence for a MAP Kinase-Dependent Mechanism. Journal of Neuroscience, 1998, 18, 7296-7305.	3.6	163
191	Bursting Dense Microspheres (Spherons) in Alzheimer's Disease. Journal of Alzheimer's Disease, 1998, 1, 1-34.	2.6	5
192	Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease. Archives of Neurology, 1999, 56, 713.	4.5	194
193	The Diagnosis of Alzheimer's Disease*. Journal of Alzheimer's Disease, 1999, 1, 249-263.	2.6	21
194	Neuroanatomy of Apraxia and Visual Agnosia in Alzheimerï¿½s Disease. , 1999, 30, 135-152.		0
195	Cognitive Support at Episodic Encoding and Retrieval: Similar Patterns of Utilization in Community-Based Samples of Alzheimer's Disease and Vascular Dementia Patients. Journal of Clinical and Experimental Neuropsychology, 1999, 21, 816-830.	1.3	41
196	Neuropsychological Performance and Cognitive Olfactory Event-Related Brain Potentials in Young and Elderly Adults. Journal of Clinical and Experimental Neuropsychology, 1999, 21, 108-126.	1.3	34
197	Progression of Alzheimer-Related Neuritic Plaque Pathology in the Entorhinal Region, Perirhinal Cortex and Hippocampal Formation. Dementia and Geriatric Cognitive Disorders, 1999, 10, 70-76.	1.5	28
198	Low amyloid (Abeta) plaque load and relative predominance of diffuse plaques distinguish argyrophilic grain disease from Alzheimer's disease. Neuropathology and Applied Neurobiology, 1999, 25, 295-305.	3.2	27
199	REVIEW: tau protein pathology in Alzheimer's disease and related disorders. Neuropathology and Applied Neurobiology, 1999, 25, 171-187.	3.2	181
200	beta-Amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer's disease. Neuropathology and Applied Neurobiology, 1999, 25, 481-491.	3.2	149
201	Frontal cortex contributes to human memory formation. Nature Neuroscience, 1999, 2, 311-314.	14.8	356
202	Remote Odor Memory in Alzheimer's Disease: Deficits as Measured by Familiarity. Journal of Adult Development, 1999, 6, 131-136.	1.4	23
203	Tangles and plaques in nondemented aging and ?preclinical? Alzheimer's disease. Annals of Neurology, 1999, 45, 358-368.	5.3	1,569
204	Soluble pool of A? amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Annals of Neurology, 1999, 46, 860-866.	5.3	1,721

#	Article	IF	Citations
205	Very Early Decline in Recognition Memory for Odors in Alzheimerâ€™s Disease. Aging, Neuropsychology, and Cognition, 1999, 6, 229-240.	1.3	16
206	A Test of Odor Fluency in Patients with Alzheimer's and Huntington's Disease. Journal of Clinical and Experimental Neuropsychology, 1999, 21, 341-351.	1.3	51
207	Unchanged levels of interleukins, neopterin, interferon-Î³ and tumor necrosis factor-Î± in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochemistry International, 1999, 34, 523-530.	3.8	66
208	Neuronal loss and Î²-amyloid removal in the amygdala of people with Down syndromeâ˜†. Neurobiology of Aging, 1999, 20, 259-269.	3.1	24
209	Normal aging and odor intensity effects on the olfactory event-related potential. International Journal of Psychophysiology, 1999, 32, 205-214.	1.0	48
210	Loss of Olfactory Function in Dementing Disease. Physiology and Behavior, 1999, 66, 177-182.	2.1	141
211	Motor cortex inhibition is not impaired in patients with Alzheimerâ€™s disease: evidence from paired transcranial magnetic stimulation. Journal of the Neurological Sciences, 1999, 170, 119-123.	0.6	71
212	Individuals with Down's syndrome demonstrate abnormal olfactory event-related potentials. Clinical Neurophysiology, 1999, 110, 1563-1569.	1.5	36
213	Entorhinal Cortex Î²-Amyloid Load in Individuals with Mild Cognitive Impairment. Experimental Neurology, 1999, 158, 469-490.	4.1	226
214	Zinc and Alzheimer's Disease: An Update. Nutritional Neuroscience, 1999, 2, 191-208.	3.1	7
215	Regional distribution of tau, Î²-amyloid and Î²-amyloid precursor protein in the AlzheimerÊ¼s brain. NeuroReport, 1999, 10, 3785-3789.	1.2	25
216	DNA Damage does not Correlate with Amyloid-ÃŸ-Plaques and Neurofibrillary Tangles in Familial Alzheimer's Disease Presenilin-1 [E280A] Mutation*. Journal of Alzheimer's Disease, 2000, 2, 47-57.	2.6	9
217	Orbital and Dorsolateral Frontal Perfusion Defect Associated With Behavioral Response to Cholinesterase Inhibitor Therapy in Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 209-218.	1.8	61
218	Sequence of AÎ²-Protein Deposition in the Human Medial Temporal Lobe. Journal of Neuropathology and Experimental Neurology, 2000, 59, 733-748.	1.7	305
219	Consequences of long-term hormone replacement therapy. British Medical Bulletin, 2000, 56, 809-823.	6.9	13
220	The frontal aging hypothesis evaluated. Journal of the International Neuropsychological Society, 2000, 6, 705-726.	1.8	252
221	Left Frontotemporal Hypoperfusion Is Associated With Aggression in Patients With Dementia. Archives of Neurology, 2000, 57, 861.	4.5	139
222	A? peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture. Journal of Neuroscience Research, 2000, 61, 449-457.	2.9	12

#	Article	IF	Citations
223	Alzheimer disease constricts the dynamic range of spatial attention in visual search. Neuropsychologia, 2000, 38, 1126-1135.	1.6	60
224	Diagnosis of Alzheimerâ€™s disease: MRI of the hippocampus vs delayed recall. Neuropsychologia, 2000, 38, 579-584.	1.6	84
225	Long-term evolution of local, proximal and remote astrocyte responses after diverse nucleus basalis lesioning (an experimental Alzheimer model): GFAP immunocytochemical study. Brain Research, 2000, 865, 245-258.	2.2	17
226	Functional brain imaging as a looking-glass into the degraded brain: reviewing evidence from Alzheimer disease in relation to normal aging. Acta Psychologica, 2000, 105, 255-277.	1.5	16
227	Mild Cognitive Impairment: Emerging Therapeutics. Annals of Pharmacotherapy, 2000, 34, 1179-1188.	1.9	10
228	Diagnosing Dementia: Interrater Reliability Assessment and Accuracy of the NINCDS/ADRDA Criteria versus CERAD Histopathological Criteria for Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2000, 11, 107-113.	1.5	43
229	Spatial Memory and Aging: Performance on a Human Analog of the Morris Water Maze. Aging, Neuropsychology, and Cognition, 2000, 7, 86-93.	1.3	114
230	Cerebral correlates of psychotic symptoms in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 167-171.	1.9	164
231	Ultrastructural evidence of fibrillar Î²-amyloid associated with neuronal membranes in behaviorally characterized aged dog brains. Neuroscience, 2000, 96, 495-506.	2.3	60
232	Olfactory event-related potentials and aging: normative data. International Journal of Psychophysiology, 2000, 36, 133-145.	1.0	116
233	The cause of neuronal degeneration in Alzheimer's disease. Progress in Neurobiology, 2000, 60, 139-165.	5.7	226
234	Formation of diffuse and fibrillar tangles in aging and early Alzheimerâ€™s diseaseâ˜†. Neurobiology of Aging, 2000, 21, 1-10.	3.1	41
235	Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimerâ€™s diseaseâ˜†. Neurobiology of Aging, 2000, 21, 19-26.	3.1	324
236	Oxidation of AÎ² and Plaque Biogenesis in Alzheimer's Disease and Down Syndrome. Neurobiology of Disease, 2001, 8, 792-806.	4.4	71
237	Apolipoprotein E Îµ4 positive individuals demonstrate delayed olfactory event-related potentials. Neurobiology of Aging, 2001, 22, 439-447.	3.1	31
238	Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiology of Aging, 2001, 22, 529-539.	3.1	511
239	Tau, Î²-amyloid and Î²-amyloid precursor protein distribution in the entorhinal-hippocampal alvear and perforant pathways in the Alzheimerâ€™s brain. Neuroscience Letters, 2001, 303, 193-197.	2.1	17
240	Age-related changes in olfactory processing detected with olfactory event-related brain potentials using velopharyngeal closure and natural breathing. International Journal of Psychophysiology, 2001, 40, 119-127.	1.0	32

#	Article	IF	Citations
241	Etiology, Genetics, and Pathogenesis of Alzheimer's Disease. , 2001, , 333-348.		0
242	Cholinergic Basal Forebrain Systems in the Primate Central Nervous System: Anatomy, Connectivity, Neurochemistry, Aging, Dementia, and Experimental Therapeutics. , 2001, , 243-281.		6
243	Olfactory centres in Alzheimer's disease: olfactory bulb is involved in early Braak's stages. NeuroReport, 2001, 12, 285-288.	1.2	212
244	Olfactory Function and Event-Related Potentials in Alzheimer's Disease. , 0, , 237-251.		0
245	Absence of cognitive impairment or decline in preclinical Alzheimerâ€™s disease. Neurology, 2001, 56, 361-367.	1.1	138
246	Olfactory-evoked regional cerebral blood flow in Alzheimer's disease.. Neuropsychology, 2001, 15, 18-29.	1.3	53
247	Amyloid, PHF-tau, Ubiquitin and Synaptic Markers in the Progression of Alzheimer's Disease: Immunochemical Analyses of Frontal Cortex from Prospectively Studied Elderly Humans. , 0, , 165-180.		5
248	Sequence of neurofibrillary changes in aging and Alzheimer's disease: A confocal study with phospho-tau antibody, AD2. Journal of Alzheimer's Disease, 2001, 3, 417-425.	2.6	42
249	Clinical Validity of AÃŸ-Protein Deposition Staging in Brain Aging and Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 946-952.	1.7	56
250	Alzheimer's disease-related synapse loss in the cingulate cortex. Journal of Alzheimer's Disease, 2001, 3, 495-505.	2.6	62
251	Fibrillar amyloid-Î² affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration. Acta Neuropathologica, 2001, 101, 585-590.	7.7	4
252	The load and distribution of Î²-amyloid in brain tissue of patients with Alzheimer's disease. Acta Neurologica Scandinavica, 2001, 103, 88-92.	2.1	23
253	The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from Î³-secretase. FEBS Journal, 2001, 268, 5329-5336.	0.2	116
254	Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease. Journal of Molecular Neuroscience, 2001, 17, 101-118.	2.3	449
255	Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease. Archives of Neurology, 2001, 58, 1395.	4.5	509
256	Tasks for Assessing Memory for Temporal Order Versus Memory for Items in Aging. Aging, Neuropsychology, and Cognition, 2001, 8, 72-78.	1.3	18
257	The Aetiology of Alzheimerâ€™s Disease: Diverse Routes into a Common Tau Pathway. , 2001, , 97-132.		1
258	The status of ongoing trials for mild cognitive impairment. Expert Opinion on Investigational Drugs, 2001, 10, 741-752.	4.1	17

#	Article	IF	Citations
259	Phases of AÎ²-deposition in the human brain and its relevance for the development of AD. Neurology, 2002, 58, 1791-1800.	1.1	2,555
260	Cerebral and hippocampal volumetry in early Alzheimer's disease. , 0, , .		2
261	Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology, 2002, 58, 750-757.	1.1	518
262	Decrements in Nuclear Glucocorticoid Receptor (GR) Protein Levels and DNA Binding in Aged Rat Hippocampus. Endocrinology, 2002, 143, 1362-1370.	2.8	79
263	Olfactory event-related potentials in Alzheimer's disease. Journal of the International Neuropsychological Society, 2002, 8, 753-763.	1.8	72
264	Olfactory acuity and cognitive function converge in older adulthood: Support for the common cause hypothesis.. Psychology and Aging, 2002, 17, 392-404.	1.6	36
265	Psychophysiology: Event-Related Potentials and Psychophysics in Dementia. , 0, , 295-308.		0
266	Phenotypic and functional changes in glial cells as a function of age. Neurobiology of Aging, 2002, 23, 105-115.	3.1	69
267	Olfactory impairment increases as a function of age in persons with Down syndrome. Neurobiology of Aging, 2002, 23, 65-73.	3.1	41
268	Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiology of Aging, 2002, 23, 547-553.	3.1	60
269	Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimerâ€™s disease. Neuroscience, 2002, 112, 75-91.	2.3	101
271	Odor Memory in Alzheimer's Disease. , 2002, , 261-277.		2
272	Loss of basal forebrain P75^{NTR} immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. Journal of Comparative Neurology, 2002, 443, 136-153.	1.6	195
273	Olfactory functional testing: sensitivity and specificity for Alzheimer's disease. Drug Development Research, 2002, 56, 123-131.	2.9	15
274	Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?. Drug Development Research, 2002, 56, 369-379.	2.9	3
275	Neuritic pathology is lacking in the entorhinal cortex, subiculum and hippocampus in middle-aged adults with schizophrenia, bipolar disorder or unipolar depression. Acta Neuropathologica, 2002, 103, 488-494.	7.7	20
276	Amyloid-Î² deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathologica, 2002, 103, 48-58.	7.7	111
277	Regulation of tau phosphorylation and protection against Î²-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disorders, 2002, 4, 153-165.	1.9	109

#	Article	IF	Citations
278	Alzheimer's Disease and the Amyloid Î² Protein. Journal of Neurochemistry, 2002, 73, 443-449.	3.9	126
279	Brain Glucose Hypometabolism after Perirhinal Lesions in Baboons: Implications for Alzheimer Disease and Aging. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1248-1261.	4.3	26
280	Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochemical Research, 2002, 27, 1035-1048.	3.3	141
281	In Vivo Brain Imaging of Tangle Burden in Humans. Journal of Molecular Neuroscience, 2002, 19, 321-328.	2.3	46
282	Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimerâ€™s disease. Neurology, 2003, 60, 1495-1500.	1.1	896
283	Distribution, progression and chemical composition of cortical amyloid-Î² deposits in aged rhesus monkeys: similarities to the human. Acta Neuropathologica, 2003, 105, 145-156.	7.7	69
284	Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease ?-amyloid protein precursor: Effect of C-terminal truncation on production of ?-amyloid protein. Journal of Neuroscience Research, 2003, 74, 378-385.	2.9	66
285	Cholesterol is necessary both for the toxic effect of AÎ² peptides on vascular smooth muscle cells and for AÎ² binding to vascular smooth muscle cell membranes. Journal of Neurochemistry, 2003, 84, 471-479.	3.9	90
286	Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Progress in Neurobiology, 2003, 71, 83-248.	5.7	176
287	Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochemistry International, 2003, 43, 191-196.	3.8	200
288	Identifying severely atrophic cortical subregions in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 797-806.	3.1	61
289	Stereologic analysis of neurofibrillary tangle formation in prefrontal cortex area 9 in aging and Alzheimerâ€™s disease. Neuroscience, 2003, 117, 577-592.	2.3	106
290	Zinc takes the center stage: its paradoxical role in Alzheimerâ€™s disease. Brain Research Reviews, 2003, 41, 44-56.	9.0	227
291	Neurofibrillary Tangles, Amyloid, and Memory in Aging and Mild Cognitive Impairment. Archives of Neurology, 2003, 60, 729.	4.5	491
292	Stereologic Evidence for Persistence of Viable Neurons in Layer II of the Entorhinal Cortex and the CA1 Field in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2003, 62, 55-67.	1.7	67
293	Loss of Calbindin-D_{28K}from Aging Human Cholinergic Basal Forebrain: Relation to Plaques and Tangles. Journal of Neuropathology and Experimental Neurology, 2003, 62, 605-616.	1.7	31
294	Left hippocampal volume loss in Alzheimer's disease is reflected in performance on odor identification: A structural MRI study. Journal of the International Neuropsychological Society, 2003, 9, 459-471.	1.8	112
295	Structural Magnetic Resonance Imaging in Established and Prodromal Alzheimer Disease: A Review. Alzheimer Disease and Associated Disorders, 2003, 17, 177-195.	1.3	88

#	Article	IF	Citations
296	Early Intervention Is Key to Successful Management of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2003, 17, S99-S104.	1.3	55
297	Functional anatomy of human odor sensation, discrimination, and identification in health and aging.. Neuropsychology, 2003, 17, 482-495.	1.3	106
298	Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: Correlation with Alzheimer's neuropathology. Journal of Alzheimer's Disease, 2003, 5, 39-48.	2.6	129
299	Neuronal Cell Death Is Preceded by Cell Cycle Events at All Stages of Alzheimer's Disease. Journal of Neuroscience, 2003, 23, 2557-2563.	3.6	441
301	The Effect of the ApoE Îµ4 Allele on Recognition Memory for Olfactory and Visual Stimuli in Patients with Pathologically Confirmed Alzheimerâ€™s Disease, Probable Alzheimerâ€™s Disease, and Healthy Elderly Controls. Journal of Clinical and Experimental Neuropsychology, 2004, 26, 779-794.	1.3	65
302	Isolated Executive Impairment and Associated Frontal Neuropathology. Dementia and Geriatric Cognitive Disorders, 2004, 17, 360-367.	1.5	27
303	Demographic and Cognitive Predictors of Cued Odor Identification: Evidence from a Population-based Study. Chemical Senses, 2004, 29, 547-554.	2.0	172
304	Neuropathologic Criteria for Diagnosing Alzheimer Disease in Persons with Pure Dementia of Alzheimer Type. Journal of Neuropathology and Experimental Neurology, 2004, 63, 1028-1037.	1.7	60
305	Ageâ€related cortical grey matter reductions in nonâ€demented Downâ€™s syndrome adults determined by MRI with voxelâ€based morphometry. Brain, 2004, 127, 811-824.	7.6	135
306	Differences in olfactory and visual memory in patients with pathologically confirmed Alzheimer's disease and the Lewy body variant of Alzheimer's disease. Journal of the International Neuropsychological Society, 2004, 10, 835-842.	1.8	33
307	Differential Vulnerability of Anterior White Matter in Nondemented Aging with Minimal Acceleration in Dementia of the Alzheimer Type: Evidence from Diffusion Tensor Imaging. Cerebral Cortex, 2004, 14, 410-423.	2.9	561
308	MRI and CSF studies in the early diagnosis of Alzheimer's disease. Journal of Internal Medicine, 2004, 256, 205-223.	6.0	185
309	A role for semaphorin 3A signaling in the degeneration of hippocampal neurons during Alzheimer's disease. Journal of Neurochemistry, 2004, 91, 716-736.	3.9	132
310	Differences between recognition memory and remote memory for olfactory and visual stimuli in nondemented elderly individuals genetically at risk for Alzheimer's disease. Experimental Gerontology, 2004, 39, 433-441.	2.8	32
311	Artificial Neural Networks and Artificial Organisms Can Predict Alzheimer Pathology in Individual Patients Only on The Basis of Cognitive and Functional Status. Neuroinformatics, 2004, 2, 399-416.	2.8	23
312	Magnetic resonance and PET studies in the early diagnosis of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2004, 4, 831-849.	2.8	41
313	A 6-Month Observational Study of the Relationship Between Weight Loss and Behavioral Symptoms in Institutionalized Alzheimer's Disease Subjects. Journal of the American Medical Directors Association, 2004, 5, 89-97.	2.5	85
314	A comparison of the sniff magnitude test and the University of Pennsylvania Smell Identification Test in children and nonnative English speakers. Physiology and Behavior, 2004, 81, 475-480.	2.1	42

#	Article	IF	Citations
315	Looking for the link between plaques and tangles. Neurobiology of Aging, 2004, 25, 735-739.	3.1	46
316	So what if tangles precede plaques?. Neurobiology of Aging, 2004, 25, 721-723.	3.1	31
317	Memory and Executive Function in Aging and AD. Neuron, 2004, 44, 195-208.	8.1	1,322
318	Î²-Secretase Activity Increases with Aging in Human, Monkey, and Mouse Brain. American Journal of Pathology, 2004, 164, 719-725.	3.8	267
319	Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease. Neurobiology of Disease, 2004, 15, 287-305.	4.4	110
320	Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiology of Aging, 2004, 25, 697-711.	3.1	219
321	Neuropathological Changes in Visuospatial Systems in Alzheimer's Disease. , 2004, 34, 30-61.		3
322	Early-Stage and Preclinical Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 163-165.	1.3	147
323	Complement Activation in Very Early Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 55-66.	1.3	99
324	2005 Potamkin Prize Awarded for Research in Early Detection of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 162.	1.3	0
325	Progress in Clinical Neurosciences: Cognitive Markers of Progression in Alzheimer's Disease. Canadian Journal of Neurological Sciences, 2005, 32, 140-151.	0.5	42
326	Eyeblink Classical Conditioning to Auditory and Olfactory Stimuli: Performance Among Older Adults With and Without the Apolipoprotein E Îµ4 Allele.. Neuropsychology, 2005, 19, 437-445.	1.3	11
327	Overlap between neurodegenerative disorders. Neuropathology, 2005, 25, 111-124.	1.2	119
328	The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. Neuropathology and Applied Neurobiology, 2005, 31, 270-279.	3.2	60
329	Natural oligomers of the amyloid-Î² protein specifically disrupt cognitive function. Nature Neuroscience, 2005, 8, 79-84.	14.8	1,595
330	Retrieval of autobiographical memory in Alzheimer's disease: Relation to volumes of medial temporal lobe and other structures. Hippocampus, 2005, 15, 535-550.	1.9	117
331	Measuring Morphological and Cellular Changes in Alzheimers Dementia: A Review Emphasizing Stereology. Current Alzheimer Research, 2005, 2, 449-481.	1.4	29
332	Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI. Nature Clinical Practice Neurology, 2005, 1, 96-105.	2.5	19

#	Article	IF	Citations
333	Odor Identification in Old Age: Demographic, Sensory and Cognitive Correlates. Aging, Neuropsychology, and Cognition, 2005, 12, 231-244.	1.3	32
334	Unequal Neuroprotection Afforded by the Acetylcholinesterase Inhibitors Galantamine, Donepezil, and Rivastigmine in SH-SY5Y Neuroblastoma Cells: Role of Nicotinic Receptors. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 1346-1353.	2.5	153
335	Neurodegenerative Memory Disorders: A potential Role of Environmental Toxins. Neurologic Clinics, 2005, 23, 485-521.	1.8	21
336	Functional Magnetic Resonance Imaging Study of Human Olfaction and Normal Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 510-514.	3.6	117
337	Apolipoprotein Îµ4 is associated with more rapid decline in odor identification than in odor threshold or Dementia Rating Scale scores. Brain and Cognition, 2005, 58, 178-182.	1.8	69
338	Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 331-354.	3.8	179
339	Î²-Amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiology of Aging, 2005, 26, 749-763.	3.1	96
340	Imaging Î²-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nuclear Medicine and Biology, 2005, 32, 337-351.	0.6	38
341	Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. Journal of Neuroscience, 2005, 25, 7709-7717.	3.6	1,839
342	Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. International Journal of Developmental Neuroscience, 2006, 24, 157-165.	1.6	142
343	Amyloid Î² and neuromelaninâ€"Toxic or protective molecules?The cellular context makes the difference. Progress in Neurobiology, 2006, 78, 364-373.	5.7	45
344	Similarities between CSFâ€"brain extracellular transfer and neurofibrillary tangle invasion in Alzheimer's disease. Neurobiology of Aging, 2006, 27, 402-412.	3.1	2
345	Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2006, 27, 1372-1384.	3.1	854
346	High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience, 2006, 143, 461-475.	2.3	162
347	Vulnerability to Alzheimer's pathology in neocortex: The roles of plasticity and columnar organization. Journal of Alzheimer's Disease, 2006, 9, 79-89.	2.6	28
348	Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 8, 359-367.	2.6	20
349	Perceived Loss of Memory Ability and Cerebral Metabolic Decline in Persons With the Apolipoprotein E-IV Genetic Risk for Alzheimer Disease. Archives of General Psychiatry, 2006, 63, 442.	12.3	28
350	Alzheimer's disease-related alterations in synaptic density: Neocortex and hippocampus. Journal of Alzheimer's Disease, 2006, 9, 101-115.	2.6	231

#	Article	IF	Citations
352	The Effects of Normal Aging on Source Memory for Odors. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2006, 61, P58-P60.	3.9	15
353	Estrogen and performance in recognition memory for olfactory and visual stimuli in females diagnosed with Alzheimer's disease. Journal of the International Neuropsychological Society, 2006, 12, 400-4.	1.8	21
354	Selective vulnerability of different types of commissural neurons for amyloid Â-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. Brain, 2006, 129, 2992-3005.	7.6	43
355	S14 TRANSGENIC MICE MODELS FOR ALZHEIMER??S DISEASE. Behavioural Pharmacology, 2006, 17, 538-539.	1.7	1
356	Gel-free analysis of the human brain proteome: Application of liquid chromatography and mass spectrometry on biopsy and autopsy samples. Proteomics, 2006, 6, 4967-4977.	2.2	18
357	The beta-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane. Journal of Neurochemistry, 2006, 96, 53-64.	3.9	30
358	Exploring a Mathematical Model for the Kinetics of Î²-Amyloid Molecular Imaging Probes through a Critical Analysis of Plaque Pathology. Molecular Imaging and Biology, 2006, 8, 151-162.	2.6	16
359	The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. Acta Neuropathologica, 2006, 112, 417-427.	7.7	32
360	Cytoarchitectonic organization of the entorhinal cortex of the canine brain. Brain Research Reviews, 2006, 52, 346-367.	9.0	13
361	Quantitative MR Imaging in Alzheimer Disease. Radiology, 2006, 241, 26-44.	7.3	112
362	Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years. Brain, 2006, 129, 2908-2922.	7.6	109
363	Xâ€34 Labeling of Abnormal Protein Aggregates During the Progression of Alzheimer's Disease. Methods in Enzymology, 2006, 412, 123-144.	1.0	52
365	Increased Neurofibrillary Tangles in the Brains of Older Pedestrians Killed in Traffic Accidents. Dementia and Geriatric Cognitive Disorders, 2006, 22, 20-26.	1.5	19
366	Biomarkers for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2007, 7, 1021-1028.	2.8	14
367	Diffusion Tensor Imaging of Normal-Appearing White Matter in Mild Cognitive Impairment and Early Alzheimer Disease: Preliminary Evidence of Axonal Degeneration in the Temporal Lobe. American Journal of Neuroradiology, 2007, 28, 1943-1948.	2.4	202
368	Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 157-161.	1.9	121
369	Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiological Genomics, 2007, 28, 311-322.	2.3	277
370	Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology, 2007, 68, 1501-1508.	1.1	676

#	Article	IF	Citations
371	Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1136-1146.	1.7	258
372	Melatonin and the aging brain. Neurochemistry International, 2007, 50, 571-580.	3.8	44
373	Apolipoprotein E É›4 Genotype and Gender: Effects on Memory. American Journal of Geriatric Psychiatry, 2007, 15, 869-878.	1.2	21
375	Morphological substrates of cognitive decline in nonagenarians and centenarians: A new paradigm?. Journal of the Neurological Sciences, 2007, 257, 72-79.	0.6	94
376	Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients. Magnetic Resonance in Medicine, 2007, 57, 172-180.	3.0	94
377	Changes in the structural complexity of the aged brain. Aging Cell, 2007, 6, 275-284.	6.7	344
378	ApoE allelic variability influences pupil response to cholinergic challenge and cognitive impairment. Genes, Brain and Behavior, 2007, 6, 209-215.	2.2	11
379	Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease. Annals of the New York Academy of Sciences, 2007, 1097, 114-145.	3.8	177
380	Plaques, Tangles, and Memory Loss in Mouse Models of Neurodegeneration. Behavior Genetics, 2007, 37, 79-100.	2.1	130
381	Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathologica, 2007, 113, 1-12.	7.7	94
382	F2-Isoprostanes as Biomarkers of Late-onset Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2007, 33, 114-119.	2.3	60
383	Immunoreactivities and Levels of Mineralocorticoid and Glucocorticoid Receptors in the Hippocampal CA1 Region and Dentate Gyrus of Adult and Aged Dogs. Neurochemical Research, 2008, 33, 562-568.	3.3	9
384	Tracing of temporo-entorhinal connections in the human brain: cognitively impaired argyrophilic grain disease cases show dendritic alterations but no axonal disconnection of temporo-entorhinal association neurons. Acta Neuropathologica, 2008, 115, 175-183.	7.7	13
385	Cerebral amyloid angiopathy and its relationship to Alzheimerâ€™s disease. Acta Neuropathologica, 2008, 115, 599-609.	7.7	288
386	1.4T study of proton magnetic relaxation rates, iron concentrations, and plaque burden in Alzheimer's disease and control postmortem brain tissue. Magnetic Resonance in Medicine, 2008, 60, 41-52.	3.0	44
387	The olfactory vector hypothesis of neurodegenerative disease: Is it viable?. Annals of Neurology, 2008, 63, 7-15.	5.3	338
388	Identification of odors of edible and nonedible stimuli as affected by age and gender. Behavior Research Methods, 2008, 40, 752-759.	4.0	29
389	Olfaction and the 5â€Year Incidence of Cognitive Impairment in an Epidemiological Study of Older Adults. Journal of the American Geriatrics Society, 2008, 56, 1517-1521.	2.6	170

#	Article	IF	Citations
390	Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radical Biology and Medicine, 2008, 45, 219-230.	2.9	95
391	Non-tau based neuronal degeneration in Alzheimer's disease â€" an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Research, 2008, 1213, 152-165.	2.2	39
392	The ubiquitinâ€proteasome system in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2008, 12, 363-373.	3.6	214
393	Parenchymal and vascular AÎ²â€deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2008, 12, 1848-1862.	3.6	109
394	Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: Insights from functional MRI studies. Neuropsychologia, 2008, 46, 1624-1635.	1.6	337
395	Plaque complement activation and cognitive loss in Alzheimer's disease. Journal of Neuroinflammation, 2008, 5, 9.	7.2	57
396	II. Temporal patterns of longitudinal change in aging brain function. Neurobiology of Aging, 2008, 29, 497-513.	3.1	32
397	Modular and laminar pathology of Brodmannâ€™s area 37 in Alzheimerâ€™s disease. Neuroscience, 2008, 152, 50-55.	2.3	29
398	Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. NeuroImage, 2008, 43, 236-244.	4.2	91
399	Differential Effects of Normal Aging on Memory for Odor-Place and Object-Place Associations. Experimental Aging Research, 2008, 34, 437-452.	1.2	18
400	The Chemical Senses and Nutrition in Older Adults. Journal of Nutrition in Gerontology and Geriatrics, 2008, 27, 247-265.	1.0	63
401	Effect of Encoding Condition on Source Memory for Odors in Healthy Young and Older Adults. Gerontology, 2008, 54, 187-192.	2.8	5
402	Neuropathology for the Neuroradiologist: Plaques and Tangles. American Journal of Neuroradiology, 2008, 29, 18-22.	2.4	42
403	Molecular Imaging and Magnetic Resonance Imaging in Early Diagnosis of Alzheimer's Disease. Neuroradiology Journal, 2008, 21, 755-771.	1.2	1
404	Molecular Aspects of Memory Dysfunction in Alzheimerâ€™s Disease. , 2008, , 245-293.		4
405	Early-Onset and Robust Amyloid Pathology in a New Homozygous Mouse Model of Alzheimer's Disease. PLoS ONE, 2009, 4, e7931.	2.5	50
406	APOE Îµ2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology, 2009, 72, 829-834.	1.1	178
407	The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals. Cerebral Cortex, 2009, 19, 497-510.	2.9	861

#	Article	IF	Citations
408	The Role of the Human Hippocampus in Odor-Place Associative Memory. Chemical Senses, 2009, 34, 513-521.	2.0	25
409	Sensory perception of food and ageing. , 2009, , 73-94.		7
410	Biomarkers of Alzheimer's disease. Neurobiology of Disease, 2009, 35, 128-140.	4.4	175
411	AÎ² aggregation and possible implications in Alzheimer's disease pathogenesis. Journal of Cellular and Molecular Medicine, 2009, 13, 412-421.	3.6	129
412	The Abnormally Phosphorylated Tau Lesion of Early Alzheimerâ€™s Disease. Neurochemical Research, 2009, 34, 118-123.	3.3	17
413	Distribution of neurofibrillary tangles in diffuse neurofibrillary tangles with calcification. Psychiatry and Clinical Neurosciences, 2009, 63, 646-651.	1.8	3
414	Olfactory Impairment in Presymptomatic Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1170, 730-735.	3.8	179
415	Olfaction in Aging and Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1170, 647-657.	3.8	36
416	Symposium Overview. Annals of the New York Academy of Sciences, 2009, 1170, 644-646.	3.8	0
417	High-throughput quantification of Alzheimerâ€™s disease pathological markers in the post-mortem human brain. Journal of Neuroscience Methods, 2009, 176, 298-309.	2.5	9
418	Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection. Pharmacological Reviews, 2009, 61, 39-61.	16.0	256
419	Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. Neurobiology of Aging, 2009, 30, 432-440.	3.1	249
420	Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiology of Aging, 2009, 30, 1125-1134.	3.1	100
421	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging, 2009, 30, 1026-1036.	3.1	558
422	Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1-14.	1.7	492
423	Recent Advances in Visualizing Alzheimers Plaques by Magnetic Resonance Imaging. Current Medical Imaging, 2009, 5, 2-9.	0.8	8
424	Amyloid Deposition and Influx Transporter Expression at the Blood-Brain Barrier Increase in Normal Aging. Journal of Neuropathology and Experimental Neurology, 2010, 69, 98-108.	1.7	94
425	Semantic networks for odors and colors in Alzheimer's disease.. Neuropsychology, 2010, 24, 291-299.	1.3	15

#	Article	IF	Citations
426	Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 36-45.	6.4	95
427	Vascular pathology in the aged human brain. Acta Neuropathologica, 2010, 119, 277-290.	7.7	275
428	Olfactory deficit detected by fMRI in early Alzheimer's disease. Brain Research, 2010, 1357, 184-194.	2.2	153
429	Characterization of AZD4694, a novel fluorinated Aî² plaque neuroimaging PET radioligand. Journal of Neurochemistry, 2010, 114, 784-794.	3.9	121
430	Yeast as a model for studying Alzheimer's disease. FEMS Yeast Research, 2010, 10, 961-969.	2.3	52
431	Pericellular innervation of neurons expressing abnormally hyperphosphorylated tau in the hippocampal formation of Alzheimerâ€™s disease patients. Frontiers in Neuroanatomy, 2010, 4, 20.	1.7	23
432	Uncovering Molecular Biomarkers That Correlate Cognitive Decline with the Changes of Hippocampus' Gene Expression Profiles in Alzheimer's Disease. PLoS ONE, 2010, 5, e10153.	2.5	121
433	Olfactory Dysfunction Correlates with Amyloid-Î² Burden in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2010, 30, 505-514.	3.6	258
434	Brain Aging in the Oldest-Old. Current Gerontology and Geriatrics Research, 2010, 2010, 1-10.	1.6	37
435	Familiarity, Cued and Free Odor Identification and Their Association with Cognitive Functioning in Middle Aged and Older Adults. Aging, Neuropsychology, and Cognition, 2010, 17, 205-219.	1.3	20
436	Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD. Current Alzheimer Research, 2010, 7, 280-286.	1.4	68
437	Differential effects of active attention and age on event-related potentials to visual and olfactory stimuli. International Journal of Psychophysiology, 2010, 78, 190-199.	1.0	19
438	Somatostatin, tau, and Î²-amyloid within the anterior olfactory nucleus in Alzheimer disease. Experimental Neurology, 2010, 223, 347-350.	4.1	55
439	Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. NeuroImage, 2010, 50, 162-174.	4.2	287
440	Should olfactory dysfunction be used as a biomarker of Alzheimerâ€™s disease?. Expert Review of Neurotherapeutics, 2010, 10, 633-635.	2.8	52
441	Decline and fall: A biological, developmental, and psycholinguistic account of deliberative language processes and ageing. Aphasiology, 2011, 25, 123-153.	2.2	11
442	Animal Models of Traumatically-Induced Dementia. Neuromethods, 2011, , 643-662.	0.3	2
443	Sensory Network Dysfunction, Behavioral Impairments, and Their Reversibility in an Alzheimer's Î²-Amyloidosis Mouse Model. Journal of Neuroscience, 2011, 31, 15962-15971.	3.6	123

#	Article	IF	Citations
444	Fractionating verbal episodic memory in Alzheimer's disease. NeuroImage, 2011, 54, 1530-1539.	4.2	164
446	Olfactory memory is impaired in a triple transgenic model of Alzheimer disease. Behavioural Brain Research, 2011, 224, 408-412.	2.2	50
447	Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology, 2011, 76, 1395-1402.	1.1	287
449	Multimodal Imaging of Alzheimer Pathophysiology in the Brain's Default Mode Network. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	2.0	26
450	Asymptomatic Alzheimers Disease: A Prodrome or a State of Resilience?. Current Alzheimer Research, 2011, 8, 330-335.	1.4	98
451	Dementia and the Default Mode. Current Alzheimer Research, 2011, 8, 361-365.	1.4	38
452	Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity. Psychiatry Research - Neuroimaging, 2011, 194, 7-13.	1.8	319
453	Functional connectivity during recognition memory in individuals genetically at risk for Alzheimer's disease. Human Brain Mapping, 2013, 34, 530-542.	3.6	18
454	Pilot data on telmisartan shortâ€term effects on glucose metabolism in the olfactory tract in Alzheimer's disease. Brain and Behavior, 2011, 1, 63-69.	2.2	8
455	Age-Related Changes in the Thickness of Cortical Zones in Humans. Brain Topography, 2011, 24, 279-291.	1.8	132
456	Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimerâ€™s disease pathology and is independent of tau, AÎ² and TDP-43 pathology. Acta Neuropathologica, 2011, 121, 635-649.	7.7	20
457	Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. Acta Neuropathologica, 2011, 122, 61-74.	7.7	151
458	Mechanisms of Neural and Behavioral Dysfunction in Alzheimerâ€™s Disease. Molecular Neurobiology, 2011, 43, 163-179.	4.0	15
459	Olfactory Dysfunction and Cognitive Impairment in Age-Related Neurodegeneration: Prevalence Related to Patient Selection, Diagnostic Criteria and Therapeutic Treatment of Aged Clients Receiving Clinical Neurology and Community-Based Care. Current Clinical Pharmacology, 2011, 6, 236-259.	0.6	18
460	Ecology of the Aging Human Brain. Archives of Neurology, 2011, 68, 1049.	4.5	161
461	Neurotoxicity Induced by Okadaic Acid in the Human Neuroblastoma SH-SY5Y Line Can Be Differentially Prevented by Î±7 and Î²2* Nicotinic Stimulation. Toxicological Sciences, 2011, 123, 193-205.	3.1	44
462	Both odor identification and ApoE-Îµ4 contribute to normative cognitive aging.. Psychology and Aging, 2011, 26, 872-883.	1.6	33
463	Microanatomical Correlates of Cognitive Ability and Decline: Normal Ageing, MCI, and Alzheimer's Disease. Cerebral Cortex, 2011, 21, 1870-1878.	2.9	49

#	Article	IF	Citations
464	Olfactory Memory Impairment in Neurodegenerative Diseases. Journal of Clinical and Diagnostic Research JCDR, 2012, 6, 1437-41.	0.8	11
465	Resting state brain networks and their implications in neurodegenerative disease. Proceedings of SPIE, 2012, , .	0.8	0
466	CSF Biomarker and PIB-PET-Derived Beta-Amyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in Nondemented Subjects. Cerebral Cortex, 2012, 22, 1993-2004.	2.9	92
467	Butyrylcholinesterase Is Associated With Î²-Amyloid Plaques in the Transgenic APP_{SWE}/PSEN1dE9 Mouse Model of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 2-14.	1.7	114
468	Differential Expression of Interneuron Populations and Correlation with Amyloid-Î² Deposition in the Olfactory Cortex of an AÎ²PP/PS1 Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 113-129.	2.6	35
469	The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. CNS Spectrums, 2012, 17, 176-206.	1.2	28
470	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain, 2012, 135, 3749-3756.	7.6	228
471	MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology, 2012, 78, 84-90.	1.1	184
472	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 215-225.	3.1	122
473	Should Alzheimer's disease be equated with human brain ageing?: A maladaptive interaction between brain evolution and senescence. Ageing Research Reviews, 2012, 11, 104-122.	10.9	18
474	Abnormal event-related potentials in young and middle-aged adults with the ApoE Îµ4 allele. International Journal of Psychophysiology, 2012, 83, 276-281.	1.0	11
475	PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 370-379.	3.8	132
476	Working memory, attention, and executive function in Alzheimerâ€™s disease and frontotemporal dementia. Cortex, 2012, 48, 429-446.	2.4	216
477	Alzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms. Antioxidants and Redox Signaling, 2012, 16, 974-1031.	5.4	163
478	Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Medicine, 2012, 10, 127.	5.5	46
479	Regional changes of cortical mean diffusivities with aging after correction of partial volume effects. NeuroImage, 2012, 62, 1705-1716.	4.2	27
480	Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. Journal of the Neurological Sciences, 2012, 322, 192-196.	0.6	25
481	The Molecular Pathology of Alzheimer's Disease. Neuroimaging Clinics of North America, 2012, 22, 11-22.	1.0	51

#	Article	IF	Citations
482	Aggregation, impaired degradation and immunization targeting of amyloid-beta dimers in Alzheimerâ€™s disease: a stochastic modelling approach. Molecular Neurodegeneration, 2012, 7, 32.	10.8	25
483	Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. Alzheimer's Research and Therapy, 2012, 4, 21.	6.2	29
484	Current Understanding and Experimental Approaches to the Study of Repetitive Brain Injury. , 2012, , .		1
485	Amygdala in Alzheimer's Disease. , 0, , .		4
486	Cholinestrase inhibitory effects of geranylated flavonoids from Paulownia tomentosa fruits. Bioorganic and Medicinal Chemistry, 2012, 20, 2595-2602.	3.0	55
487	Olfactory ERPs in an odor/visual congruency task differentiate ApoE Îµ4 carriers from non-carriers. Brain Research, 2012, 1442, 55-65.	2.2	28
488	Hippocampal Subregions are Differentially Affected in the Progression to Alzheimer's Disease. Anatomical Record, 2012, 295, 132-140.	1.4	34
489	Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimerâ€™s disease measured by pulsed arterial spin labeling MRI. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 69-77.	3.2	103
490	APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2013, 37, 1322-1335.	6.1	98
491	Pathology of clinical and preclinical Alzheimerâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 137-145.	3.2	51
492	Amyloid PET Imaging. PET Clinics, 2013, 8, 431-445.	3.0	2
493	Glutamine synthetase in astrocytes from entorhinal cortex of the triple transgenic animal model of Alzheimerâ€™s disease is not affected by pathological progression. Biogerontology, 2013, 14, 777-787.	3.9	26
494	Vascular Aspects of Cognitive Impairment and Dementia. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1696-1706.	4.3	124
495	A brief olfactory test for Alzheimer's disease. Journal of the Neurological Sciences, 2013, 333, 19-24.	0.6	73
496	Mechanisms of Protein Seeding in Neurodegenerative Diseases. JAMA Neurology, 2013, 70, 304.	9.0	195
497	Age-related loss of noradrenergic neurons in the brains of triple transgenic mice. Age, 2013, 35, 139-147.	3.0	43
498	The effects of aging and Alzheimer's disease on cerebral cortical anatomy: Specificity and differential relationships with cognition. NeuroImage, 2013, 76, 332-344.	4.2	201
499	Inhibitory Neuron and Hippocampal Circuit Dysfunction in an Aged Mouse Model of Alzheimer's Disease. PLoS ONE, 2013, 8, e64318.	2.5	73

#	Article	IF	Citations
500	Amyloid Beta Inhibits Olfactory Bulb Activity and the Ability to Smell. PLoS ONE, 2013, 8, e75745.	2.5	44
501	Age and apolipoprotein E Îµ4 effects on neural correlates of odor memory.. Behavioral Neuroscience, 2013, 127, 339-349.	1.2	11
502	Interneurons and Betaâ€Amyloid in the Olfactory Bulb, Anterior Olfactory Nucleus and Olfactory Tubercle in APPxPS1 Transgenic Mice Model of Alzheimer's Disease. Anatomical Record, 2013, 296, 1413-1423.	1.4	30
503	Longitudinal Monitoring of Sex-Related in vivo Metabolic Changes in the Brain of Alzheimer's Disease Transgenic Mouse Using Magnetic Resonance Spectroscopy. Journal of Alzheimer's Disease, 2013, 34, 1051-1059.	2.6	20
505	Cerebral Microvascular Rather than Parenchymal Amyloid-Î² Protein Pathology Promotes Early Cognitive Impairment in Transgenic Mice. Journal of Alzheimer's Disease, 2013, 38, 621-632.	2.6	40
506	Brain [18F]FDDNP Binding and Glucose Metabolism in Advanced Elderly Healthy Subjects and Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2013, 36, 311-320.	2.6	20
507	Hereditary and sporadic beta-amyloidoses. Frontiers in Bioscience - Landmark, 2013, 18, 1202.	3.0	9
508	MR Microscopy of Human Amyloid-Î² Deposits: Characterization of Parenchymal Amyloid, Diffuse Plaques, and Vascular Amyloid. Journal of Alzheimer's Disease, 2013, 34, 1037-1049.	2.6	17
509	Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease. Current Enzyme Inhibition, 2013, 9, 46-54.	0.4	1
511	Pharmacotherapy of Alzheimerâ€™s Disease: Current State and Future Perspectives. , 2014, , 3-39.		5
512	Amyloid-beta accumulation, neurogenesis, behavior, and the age of rats.. Behavioral Neuroscience, 2014, 128, 523-536.	1.2	29
513	Tau PET Imaging in Alzheimerâ€™s Disease. Current Neurology and Neuroscience Reports, 2014, 14, 500.	4.2	141
514	Region-Specific Expression of Tau, Amyloid-Î² Protein Precursor, and Synaptic Proteins at Physiological Condition or Under Endoplasmic Reticulum Stress in Rats. Journal of Alzheimer's Disease, 2014, 41, 1149-1163.	2.6	23
515	Modulatory role of the prefrontal generator within the auditory M50 network. NeuroImage, 2014, 92, 120-131.	4.2	16
516	Phosphorylated Tau-AÎ²42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimerâ€™s Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid. Biological Psychiatry, 2014, 75, 723-731.	1.3	72
517	Spreading of Amyloid, Tau, and Microvascular Pathology in Alzheimer's Disease: Findings from Neuropathological and Neuroimaging Studies. Journal of Alzheimer's Disease, 2014, 42, S421-S429.	2.6	75
518	Neuropathologic assessment of participants in two multiâ€center longitudinal observational studies: The <scp>A</scp>lzheimer <scp>D</scp>isease <scp>N</scp>euroimaging <scp>I</scp>nitiative (<scp>ADNI</scp>) and the <scp>D</scp>ominantly <scp>I</scp>nherited <scp>A</scp>lzheimer <scp>N</scp>etwork (<scp>DIAN</scp>). Neuropathology, 2015, 35, 390-400.	1.2	68
519	Protein Folding and Mechanisms of Proteostasis. International Journal of Molecular Sciences, 2015, 16, 17193-17230.	4.1	210

#	Article	IF	Citations
520	Connectivity of Pathology: The Olfactory System as a Model for Network-Driven Mechanisms of Alzheimerâ€™s Disease Pathogenesis. Frontiers in Aging Neuroscience, 2015, 7, 234.	3.4	37
521	Altered Functional Connectivity of Fusiform Gyrus in Subjects with Amnestic Mild Cognitive Impairment: A Resting-State fMRI Study. Frontiers in Human Neuroscience, 2015, 9, 471.	2.0	47
522	The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimerâ€™s Disease and Vascular Dementia. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-8.	4.0	115
523	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nature Neuroscience, 2015, 18, 800-806.	14.8	582
524	An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies. Neurodegenerative Diseases, 2015, 15, 301-312.	1.4	53
525	The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2015, 36, 2093-2117.	3.6	54
526	Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies. Journal of Neural Transmission, 2015, 122, 1007-1018.	2.8	47
527	An odor identification approach based on event-related pupil dilation and gaze focus. International Journal of Psychophysiology, 2015, 96, 201-209.	1.0	9
528	Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1492-1506.	6.4	11
529	In-vivoandin-vitrotechniques used to investigate Alzheimer's disease. Frontiers in Life Science: Frontiers of Interdisciplinary Research in the Life Sciences, 2015, 8, 332-347.	1.1	13
530	HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?. Alzheimer's Research and Therapy, 2015, 7, 37.	6.2	114
531	Olfactory Dysfunction in ApoE É›4/4 Homozygotes with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 791-803.	2.6	21
532	Semaphorins. , 2015, , .		6
533	Olfactory Cortex Degeneration in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 45, 947-958.	2.6	106
534	Paradigm shift redefining molecular, metabolic and structural events in Alzheimerâ€™s disease involves a proposed contribution by transition metals. Defined lengthy preclinical stage provides new hope to circumvent advancement of disease- and age-related neurodegeneration. Medical Hypotheses, 2015, 84, 460-469.	1.5	11
535	Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain, 2015, 138, 3734-3746.	7.6	101
536	The Roots of Alzheimer's Disease: Are High-Expanding Cortical Areas Preferentially Targeted?. Cerebral Cortex, 2015, 25, 2556-2565.	2.9	16
537	Neuropathology and biochemistry of AÎ² and its aggregates in Alzheimerâ€™s disease. Acta Neuropathologica, 2015, 129, 167-182.	7.7	224

#	Article	IF	Citations
538	Neuroanatomy and Pathology of Sporadic Alzheimer's Disease. Advances in Anatomy, Embryology and Cell Biology, 2015, , .	1.6	81
539	Interneurons, tau and amyloid-Î² in the piriform cortex in Alzheimerâ€™s disease. Brain Structure and Function, 2015, 220, 2011-2025.	2.3	64
540	Anticancer and Antineurodegenerative Effects of Ginsenosides. Studies in Natural Products Chemistry, 2016, 50, 131-158.	1.8	2
541	Fus1 KO Mouse As a Model of Oxidative Stress-Mediated Sporadic Alzheimer's Disease: Circadian Disruption and Long-Term Spatial and Olfactory Memory Impairments. Frontiers in Aging Neuroscience, 2016, 8, 268.	3.4	25
542	Selenomethionine Ameliorates Neuropathology in the Olfactory Bulb of a Triple Transgenic Mouse Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2016, 17, 1595.	4.1	12
543	Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives. Korean Journal of Radiology, 2016, 17, 827.	3.4	61
544	Volume Loss of the Nucleus Basalis of Meynert is Associated with Atrophy of Innervated Regions in Mild Cognitive Impairment. Cerebral Cortex, 2016, 27, 3881-3889.	2.9	39
545	Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimerâ€™s Disease. Journal of the International Neuropsychological Society, 2016, 22, 978-990.	1.8	20
546	Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease. Neurobiology of Aging, 2016, 42, 80-90.	3.1	25
547	The Pathophysiology of Concussion. Current Pain and Headache Reports, 2016, 20, 42.	2.9	81
548	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex, 2016, 83, 124-135.	2.4	21
549	Animal Models of Behavior Genetics. , 2016, , .		0
550	Network-Based Statistic Show Aberrant Functional Connectivity in Alzheimer's Disease. IEEE Journal on Selected Topics in Signal Processing, 2016, 10, 1182-1188.	10.8	22
551	Neurodegenerative Diseases and Dementia. , 2016, , 167-197.		0
552	Multimodal Magnetic Resonance Imaging in Alzheimerâ€™s Disease Patients at Prodromal Stage. Journal of Alzheimer's Disease, 2016, 50, 1035-1050.	2.6	26
553	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	7.6	150
554	Cognitive decline in normal aging and early Alzheimerâ€™s disease: A continuous or discontinuous transition? A historical review and future research proposal. Cogent Psychology, 2016, 3, 1185226.	1.3	4
555	Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics. Neurotoxicity Research, 2016, 30, 677-697.	2.7	78

#	Article	IF	Citations
556	Cerebral and blood correlates of reduced functional connectivity in mild cognitive impairment. Brain Structure and Function, 2016, 221, 631-645.	2.3	16
557	Microtubule Dynamics in Neuronal Development, Plasticity, and Neurodegeneration. International Review of Cell and Molecular Biology, 2016, 321, 89-169.	3.2	79
558	Long-term episodic memory decline is associated with olfactory deficits only in carriers of ApoE-Ñ”4. Neuropsychologia, 2016, 85, 1-9.	1.6	46
559	Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer's disease pathology. Neurobiology of Aging, 2016, 42, 1-12.	3.1	69
560	Interneurons in the human olfactory system in Alzheimer's disease. Experimental Neurology, 2016, 276, 13-21.	4.1	36
561	Olfactory function in neuropsychiatric disorders. Psychiatry Research, 2017, 252, 175-179.	3.3	13
562	Mitophagy and Alzheimerâ€™s Disease: Cellular and Molecular Mechanisms. Trends in Neurosciences, 2017, 40, 151-166.	8.6	553
563	Multiregional Age-Associated Reduction of Brain Neuronal Reserve Without Association With Neurofibrillary Degeneration or Î²-Amyloidosis. Journal of Neuropathology and Experimental Neurology, 2017, 76, 439-457.	1.7	14
564	Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Nonâ€“Alzheimer Disease Dementias. PET Clinics, 2017, 12, 351-359.	3.0	21
565	Alzheimer's disease: The next frontierâ€”Special Report 2017. Alzheimer's and Dementia, 2017, 13, 374-380.	0.8	88
566	Central Olfactory Dysfunction inÂAlzheimerâ€™s Disease and Mild Cognitive Impairment: A Functional MRI Study. Journal of Alzheimer's Disease, 2017, 59, 359-368.	2.6	50
567	In vivo staging of regional amyloid deposition. Neurology, 2017, 89, 2031-2038.	1.1	321
568	Hierarchical Subcortical Sub-Regional Shape Network Analysis in Alzheimerâ€™s Disease. Neuroscience, 2017, 366, 70-83.	2.3	7
569	Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus. Neuropathology and Applied Neurobiology, 2017, 43, 571-583.	3.2	7
570	Age-Related Changes in Human and Nonhuman Timing. Timing and Time Perception, 2017, 5, 261-279.	0.6	16
571	Molecular Mechanisms of Synaptic Plasticity and Memory andÂTheir Dysfunction in Alzheimer's Disease â˜†. , 2017, , 65-135.		1
572	Blood-based immunoassay of tau proteins for early diagnosis of Alzheimer's disease using surface plasmon resonance fiber sensors. RSC Advances, 2018, 8, 7855-7862.	3.6	38
573	Human Apolipoprotein E Genotype Differentially Affects Olfactory Behavior and Sensory Physiology in Mice. Neuroscience, 2018, 380, 103-110.	2.3	15

#	Article	IF	Citations
574	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.8	5,861
575	Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology, 2018, 90, e1047-e1056.	1.1	36
576	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 2-20.	1.7	77
577	The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiology of Disease, 2018, 109, 226-248.	4.4	214
578	Variations in Acetylcholinesterase Activity within Human Cortical Pyramidal Neurons Across Age and Cognitive Trajectories. Cerebral Cortex, 2018, 28, 1329-1337.	2.9	32
579	Sex- and age-specific modulation of brain GABA levels in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2018, 62, 168-179.	3.1	38
580	Microglial activation occurs late during preclinical Alzheimer's disease. Glia, 2018, 66, 2550-2562.	4.9	61
581	"APP"reciating the complexity of HIV-induced neurodegenerative diseases. PLoS Pathogens, 2018, 14, e1007309.	4.7	4
582	Proteomic Investigation of Murine Neuronal Î±7-Nicotinic Acetylcholine Receptor Interacting Proteins. Journal of Proteome Research, 2018, 17, 3959-3975.	3.7	8
583	Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimerâ€™s disease: a longitudinal cohort study. Alzheimer's Research and Therapy, 2018, 10, 88.	6.2	15
584	O-GlcNAcylation and neuronal energy status: Implications for Alzheimerâ€™s disease. Ageing Research Reviews, 2018, 46, 32-41.	10.9	25
585	Hippocampal projections to the anterior olfactory nucleus differentially convey spatiotemporal information during episodic odour memory. Nature Communications, 2018, 9, 2735.	12.8	62
586	Stereological Quantification of Plaques and Tangles in Neocortex from Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2018, 64, 723-734.	2.6	4
587	Theories of Aging and the Prevalence of Alzheimerâ€™s Disease. BioMed Research International, 2019, 2019, 1-9.	1.9	65
588	Relationships Between Diffusion Tensor Imaging and Cerebrospinal Fluid Metrics in Early Stages of the Alzheimerâ€™s Disease Continuum. Journal of Alzheimer's Disease, 2019, 70, 965-981.	2.6	20
589	An experimental model of Braakâ€™s pretangle proposal for the origin of Alzheimerâ€™s disease: the role of locus coeruleus in early symptom development. Alzheimer's Research and Therapy, 2019, 11, 59.	6.2	37
590	Emotion regulation across the life span. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 163, 257-280.	1.8	30
591	Accelerated Ovarian Failure as a Unique Model to Study Peri-Menopause Influence on Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 242.	3.4	25

#	Article	IF	Citations
592	Cerebral Amyloid Angiopathy, Alzheimerâ€™s Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets. NeuroMolecular Medicine, 2019, 21, 369-390.	3.4	18
593	Computational identification of key genes that may regulate gene expression reprogramming in Alzheimerâ€™s patients. PLoS ONE, 2019, 14, e0222921.	2.5	22
594	Differential Effects of BMI on Brain Response to Odor in Olfactory, Reward and Memory Regions: Evidence from fMRI. Nutrients, 2019, 11, 926.	4.1	24
595	2019 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2019, 15, 321-387.	0.8	1,633
596	Lifespan Changes of the Human Brain In Alzheimerâ€™s Disease. Scientific Reports, 2019, 9, 3998.	3.3	113
597	In vivo localization of human acetylcholinesterase-derived species in a Î²-sheet conformation at the core of senile plaques in Alzheimer's disease. Journal of Biological Chemistry, 2019, 294, 6253-6272.	3.4	19
598	Different aspects of Alzheimerâ€™s disease-related amyloid Î²-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Acta Neuropathologica Communications, 2019, 7, 178.	5.2	29
599	Neuroimaging modality fusion in Alzheimerâ€™s classification using convolutional neural networks. PLoS ONE, 2019, 14, e0225759.	2.5	38
600	In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies. Neurobiology of Aging, 2019, 74, 171-181.	3.1	21
601	Olfactory and other sensory impairments in Alzheimer disease. Nature Reviews Neurology, 2019, 15, 11-24.	10.1	234
602	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 89-102.	7.7	64
603	To stage, or not to stage. Current Opinion in Neurobiology, 2020, 61, 10-22.	4.2	37
604	The Relation Between Personality and Biomarkers in Sensitivity and Conversion to Alzheimer-Type Dementia. Journal of the International Neuropsychological Society, 2020, 26, 596-606.	1.8	23
605	Optimized Electrode Placements for Non-invasive Electrical Stimulation of the Olfactory Bulb and Olfactory Mucosa. Frontiers in Neuroscience, 2020, 14, 581503.	2.8	6
606	The Neuroprotective Action of Amidated-Kyotorphin on Amyloid Î² Peptide-Induced Alzheimerâ€™s Disease Pathophysiology. Frontiers in Pharmacology, 2020, 11, 985.	3.5	9
607	Novel MRI Techniques Identifying Vascular Leak and Paravascular Flow Reduction in Early Alzheimer Disease. Biomedicines, 2020, 8, 228.	3.2	15
608	Perspectives on the Intracellular Bacterium Chlamydia pneumoniae in Late-Onset Dementia. Current Clinical Microbiology Reports, 2020, 7, 90-99.	3.4	1
609	Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders. International Journal of Molecular Sciences, 2020, 21, 6070.	4.1	36

#	Article	IF	Citations
610	The coarse-grained plaque: a divergent AÎ² plaque-type in early-onset Alzheimerâ€™s disease. Acta Neuropathologica, 2020, 140, 811-830.	7.7	45
611	Extracellular Sortilin Proteopathy Relative to Î²-Amyloid and Tau in Aged and Alzheimerâ€™s Disease Human Brains. Frontiers in Aging Neuroscience, 2020, 12, 93.	3.4	10
612	Older, non-demented apolipoprotein Îµ4 carrier males show hyperactivation and structural differences in odor memory regions: a blood-oxygen-level-dependent and structural magnetic resonance imaging study. Neurobiology of Aging, 2020, 93, 25-34.	3.1	4
613	PLA2G4E, a candidate gene for resilience in AlzheimerÂ´s disease and a new target for dementia treatment. Progress in Neurobiology, 2020, 191, 101818.	5.7	23
614	Alzheimerâ€™s Disease: What Can We Learn From the Peripheral Olfactory System?. Frontiers in Neuroscience, 2020, 14, 440.	2.8	30
615	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
616	Amyloid-Î², tau, and the cholinergic system in Alzheimerâ€™s disease: seeking direction in a tangle of clues. Reviews in the Neurosciences, 2020, 31, 391-413.	2.9	56
617	Inhibition of 5Î± Reductase Impairs Cognitive Performance, Alters Dendritic Morphology and Increases Tau Phosphorylation in the Hippocampus of Male 3xTg-AD Mice. Neuroscience, 2020, 429, 185-202.	2.3	14
618	Intranasal glyphosate-based herbicide administration alters the redox balance and the cholinergic system in the mouse brain. NeuroToxicology, 2020, 77, 205-215.	3.0	22
619	Nanoformulations of Herbal Extracts in Treatment of Neurodegenerative Disorders. Frontiers in Bioengineering and Biotechnology, 2020, 8, 238.	4.1	98
620	The Brief Form of the California Odor Learning Test 3. Frontiers in Neuroscience, 2020, 14, 173.	2.8	3
621	An evaluation of the amyloid cascade model using in vivo positron emission tomographic imaging. Psychogeriatrics, 2021, 21, 14-23.	1.2	3
622	Potential neurotoxins: Okadaic acid and analogs. Advances in Neurotoxicology, 2021, 6, 193-221.	1.9	0
623	Environmental exposures and the etiopathogenesis of Alzheimer's disease: The potential role of BACE1 as a critical neurotoxic target. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22694.	3.0	12
624	Magnetic Resonance Imaging for Drug Development. Advances in Experimental Medicine and Biology, 2021, 1310, 187-209.	1.6	0
625	Genetic Aspects of Early-Onset Alzheimerâ€™s Disease. , 2021, , 29-39.		0
626	Nonphosphorylated tau slows down AÎ²1â€“42 aggregation, binds to AÎ²1â€“42 oligomers, and reduces AÎ²1â€“42 toxicity. Journal of Biological Chemistry, 2021, 296, 100664.	3.4	3
627	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	5.2	17

#	Article	IF	Citations
628	The Role of Microglia in Sporadic Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 79, 961-968.	2.6	43
629	Could COVID-19 anosmia and olfactory dysfunction trigger an increased risk of future dementia in patients with ApoE4?. Medical Hypotheses, 2021, 147, 110479.	1.5	17
630	Semaphorins in Adult Nervous System Plasticity and Disease. Frontiers in Synaptic Neuroscience, 2021, 13, 672891.	2.5	52
631	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. Journal of Alzheimer's Disease, 2021, 82, 381-390.	2.6	8
632	Specific neuronal subpopulations in the rat basolateral amygdala express high levels of nonphosphorylated neurofilaments. Journal of Comparative Neurology, 2021, 529, 3292-3312.	1.6	4
633	Ganoderic Acid A Promotes Amyloid-Î² Clearance (In Vitro) and Ameliorates Cognitive Deficiency in Alzheimerâ€™s Disease (Mouse Model) Through Autophagy Induced by Activating Axl. International Journal of Molecular Sciences, 2021, 22, 5559.	4.1	22
634	Olfaction and anosmia: From ancient times to COVID-19. Journal of the Neurological Sciences, 2021, 425, 117433.	0.6	7
635	Comparative neuropathology in aging primates: A perspective. American Journal of Primatology, 2021, 83, e23299.	1.7	11
636	Objective Assessment of Hyposmia in Alzheimer's Disease From Image and Behavior by Combining Pleasant Odor With Unpleasant Odor. Frontiers in Neurology, 2021, 12, 697487.	2.4	2
637	Oxygen Sensing and Signaling in Alzheimerâ€™s Disease: A Breathtaking Story!. Cellular and Molecular Neurobiology, 2022, 42, 3-21.	3.3	6
638	Magnetic resonance imaging biomarkers for cognitive decline in Down syndrome. , 2022, , 149-172.		2
639	Aging-Dependent Mitophagy Dysfunction in Alzheimerâ€™s Disease. Molecular Neurobiology, 2021, 58, 2362-2378.	4.0	25
640	What's that smell? A pictorial review of the olfactory pathways and imaging assessment of the myriad pathologies that can affect them. Insights Into Imaging, 2021, 12, 7.	3.4	10
641	Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease. Archives of Neurology, 1998, 55, 1185-1191.	4.5	275
642	Cognition in Rodents. , 2009, , 159-174.		2
643	Cortical Destruction and Cell Death in Alzheimerâ€™s Disease. , 1999, , 497-510.		4
644	Animal Models of General Cognitive Ability for Genetic Research into Cognitive Functioning. , 2014, , 257-278.		10
645	Temporal Sequence of Alzheimerâ€™s Disease-Related Pathology. Cerebral Cortex, 1999, , 475-512.	0.6	71

#	Article	IF	Citations
646	Vascular-Related and Mediated Alterations in Alzheimerâ€™s Disease. Cerebral Cortex, 1999, , 733-772.	0.6	6
647	Cortical Neuropathology in Aging and Dementing Disorders. Cerebral Cortex, 1999, , 175-311.	0.6	25
648	Glial Activation as a Common Denominator in Neurodegenerative Disease: A Hypothesis in Neuropathophysiology. , 1993, , 359-381.		4
649	Magnetic Resonance Imaging of Brain Iron. , 1997, , 41-56.		4
650	Early Diagnosis of Alzheimerâ€™s Disease. , 2000, , 1-27.		11
651	Pathological Diagnosis of Alzheimerâ€™s Disease. , 2000, , 65-82.		5
653	Melatonin, Oxidative Stress, and the Aging Brain. , 2010, , 339-357.		4
654	The Involvement of AÎ² in the Neuroinflammatory Response. , 2007, , 52-82.		1
655	The Pattern of Lesions During the Transition to the Symptomatic Phase and in Fully Developed Alzheimerâ€™s Disease. Advances in Anatomy, Embryology and Cell Biology, 2015, , 95-130.	1.6	2
656	Aspects of Cortical Destruction in Alzheimerâ€™s Disease. , 1997, , 1-16.		9
657	Connections and Cognitive Impairment in Alzheimerâ€™s Disease. , 1997, , 149-166.		11
658	The neuropathological diagnosis of Alzheimer disease. Journal of Neural Transmission Supplementum, 1998, 53, 97-118.	0.5	76
659	Mild cognitive impairment â€" an early stage of Alzheimerâ€™s disease?. Journal of Neural Transmission Supplementum, 1998, 54, 21-29.	0.5	73
660	Neuropathology of Alzheimerâ€™s disease: a critical update. Journal of Neural Transmission Supplementum, 1998, 54, 77-95.	0.5	196
661	Evolution of Alzheimerâ€™s disease related cortical lesions. Journal of Neural Transmission Supplementum, 1998, 54, 97-106.	0.5	115
662	Classification of dementias based on functional morphology. Key Topics in Brain Research, 1994, , 9-39.	0.2	7
663	Amyloid-Î² and Tau at theÂCrossroads of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1184, 187-203.	1.6	115
664	Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathologica, 1994, 87, 456-468.	7.7	8

#	Article	IF	Citations
665	Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathologica, 1994, 87, 469-480.	7.7	20
666	Senile plaques in temporal lobe epilepsy. Acta Neuropathologica, 1994, 87, 504-510.	7.7	14
667	Senile plaques do not progressively accumulate with normal aging. Acta Neuropathologica, 1994, 87, 520-525.	7.7	14
668	Cortical and striatal neurone number in Huntington's disease. Acta Neuropathologica, 1994, 88, 320-333.	7.7	12
669	Types of Age-Related Brain Lesions and Relationship to Neuropathologic Diagnostic Systems of Alzheimer's Disease. , 2001, , 65-76.		2
670	Morphological Changes in Human Cerebral Cortex during Normal Aging. , 2001, , 77-84.		2
671	Neurobiological Models of Aging in the Dog and Other Vertebrate Species. , 2001, , 457-468.		27
672	Glucocorticoids and the Aging Brain: Cause or Consequence?. , 2001, , 883-905.		6
673	Excitotoxic lesions centered on perirhinal cortex produce delay-dependent deficits in a test of spatial memory.. Behavioral Neuroscience, 1998, 112, 512-524.	1.2	24
674	Olfactory-evoked regional cerebral blood flow in Alzheimer's disease.. Neuropsychology, 2001, 15, 18-29.	1.3	27
675	Brain Glucose Hypometabolism After Perirhinal Lesions in Baboons: Implications for Alzheimer Disease and Aging. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1248-1261.	4.3	7
676	Frontal Brain and Leptomeningeal Biopsy Specimens Correlated with Cerebrospinal Fluid Outflow Resistance and B-wave Activity in Patients Suspected of Normal-pressure Hydrocephalus. Neurosurgery, 1997, 40, 497-502.	1.1	49
677	The utility of olfactory function in distinguishing early-stage Alzheimer's disease from HIV-associated neurocognitive disorders. Aids, 2021, 35, 429-437.	2.2	8
678	Alzheimer's disease-like perturbations in HIV-mediated neuronal dysfunctions: understanding mechanisms and developing therapeutic strategies. Open Biology, 2020, 10, 200286.	3.6	19
679	Neurodegeneration in Normal Brain Aging and Disease. Science of Aging Knowledge Environment: SAGE KE, 2004, 2004, pe26-pe26.	0.8	106
680	The Development of Amyloid beta Protein Deposits in the Aged Brain. Science of Aging Knowledge Environment: SAGE KE, 2006, 2006, re1-re1.	0.8	174
681	Is Alzheimerâ€™s disease inevitable with age?. Journal of Clinical Investigation, 1999, 104, 1171-1173.	8.2	47
682	Frontal Brain and Leptomeningeal Biopsy Specimens Correlated with Cerebrospinal Fluid Outflow Resistance and B-wave Activity in Patients Suspected of Normal-pressure Hydrocephalus. Neurosurgery, 1997, 40, 497-502.	1.1	54

#	Article	IF	Citations
684	hESC-secreted proteins can be enriched for multiple regenerative therapies by heparin-binding. Aging, 2013, 5, 357-372.	3.1	13
685	Olfactory phenotypic expression unveils human aging. Oncotarget, 2016, 7, 19193-19200.	1.8	16
686	Smell and taste recognition in early stages of late-onset Alzheimerâ€™s disease. SURG Journal, 2010, 4, 57-64.	0.1	1
687	The Amyloid Cascade Hypothesis in Alzheimerâ€™s Disease: Itâ€™s Time to Change Our Mind. Current Neuropharmacology, 2017, 15, 926-935.	2.9	253
688	Gonadotropin-Releasing Hormone Receptor System: Modulatory Role in Aging and Neurodegeneration. CNS and Neurological Disorders - Drug Targets, 2010, 9, 651-660.	1.4	57
689	A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimerâ€™s Disease Pathogenicity: An Update. CNS and Neurological Disorders - Drug Targets, 2014, 13, 383-390.	1.4	41
690	At the Crossroads Between Neurodegeneration and Cancer: A Review of Overlapping Biology and Its Implications. Current Aging Science, 2019, 11, 77-89.	1.2	67
692	Age-related mild cognitive deficit: a ready-to-use concept?. Dialogues in Clinical Neuroscience, 2003, 5, 61-76.	3.7	6
693	Is there a neuropathology difference between mild cognitive impairment and dementia?. Dialogues in Clinical Neuroscience, 2009, 11, 171-179.	3.7	38
694	Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition. Neural Regeneration Research, 2018, 13, 1719.	3.0	59
695	Cognitive assessment in Alzheimerâ€™s disease. Advances in Alzheimer's Disease, 2013, 02, 123-125.	0.9	4
696	Neural Basis of Hyposmia in Alzheimerâ€™s Disease. , 0, , .		2
697	Olfactory Dysfunctions in Alzheimerâ€™s Disease. , 0, , .		3
699	Olfactory Measures as Predictors of Conversion to Mild Cognitive Impairment and Alzheimerâ€™s Disease. Brain Sciences, 2021, 11, 1391.	2.3	10
701	Longevity and Brain Aging: The Paradigm of Centenarians. , 2001, , 85-93.		0
702	Patterns of Tissue Pathology in Neurological Diseases. , 2002, , 49-55.		0
704	F2-Isoprostanes as Biomarkers of Late Onset Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2005, , 147-157.	0.3	0
705	Olfaction and Aging. , 2006, , 173-180.		1

#	Article	IF	Citations
707	Le cerveau aux limites du vieillissement: Ã propos des nonagÃ©naires et centenaires. Swiss Archives of Neurology, Psychiatry and Psychotherapy, 2008, 159, 386-393.	0.0	0
708	Microstructural Imaging of Neurodegenerative Changes. , 2009, , 95-117.		1
709	Alzheimerâ€™s Disease: Neurodegeneration. , 2009, , 275-281.		0
710	3 Neuropathology of Aging. , 2009, , 27-40.		1
711	Genomic Linkage Between Alzheimer's Disease and Type 2 Diabetes. CNS and Neurological Disorders - Drug Targets, 2014, 13, 203-212.	1.4	1
712	Olfactory Bulb Involvement in AD: An Early Change. , 1994, , 34-40.		0
713	The Roles of Zinc and Copper in the Function and Metabolism of the Amyloid Protein Precursor Superfamily. , 1994, , 169-180.		0
714	Relationship of plaques and tangles to Alzheimer's disease phenotype. , 1995, , 193-223.		3
715	Pathological Changes in the Elderly Human Brain. , 1997, , 5-114.		0
716	Pathological Changes in Neurodegenerative Disease. , 1997, , 115-152.		0
717	Relationships Between Aging and Neurodegenerative Disease. , 1997, , 187-196.		0
718	Anatomy of Pathological Alterations in Alzheimerâ€™s Disease. , 1997, , 219-223.		0
719	Neuronal anion exchange proteins in Alzheimerâ€™s disease pathology. Journal of Neural Transmission Supplementum, 1998, , 249-257.	0.5	0
720	Semaphorins and Neurodegenerative Disorders. , 2015, , 189-205.		0
722	ALZHEIMERâ€™S DISEASE: A CONSEQUENCE OF IMPAIRED MITOPHAGY?. Asian Journal of Pharmaceutical and Clinical Research, 0, , 75-80.	0.3	1
724	A smaller olfactory bulb in a mouse model of Down syndrome. Acta Neurobiologiae Experimentalis, 2020, 80, 375-380.	0.7	1
725	The Correlation Between Olfactory Test and Hippocampal Volume in Alzheimer's Disease and Mild Cognitive Impairment Patients: A Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 755160.	3.4	5
726	Synaptic Pathology in Dementia. , 2006, , 431-443.		0

#	Article	IF	Citations
727	Brain, Head, and Neck. , 2008, , 169-533.		1
728	Causes of Alzheimer's disease. Cmaj, 2000, 162, 65-72.	2.0	26
729	Casein kinase II alteration precedes tau accumulation in tangle formation. American Journal of Pathology, 1992, 140, 263-8.	3.8	51
730	Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. American Journal of Pathology, 1993, 143, 565-78.	3.8	85
735	Functional assessment of magno, parvo and konio-cellular pathways; current state and future clinical applications. Journal of Ophthalmic and Vision Research, 2011, 6, 119-26.	1.0	31
737	Changes in brain morphology in Alzheimer disease and normal aging: is Alzheimer disease an exaggerated aging process?. American Journal of Neuroradiology, 2001, 22, 1680-5.	2.4	122
738	An insight into Alzheimerâ€™s disease and its on-setting novel genes. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	1.0	4
739	Specific neuronal subpopulations in the amygdala of macaque monkeys express high levels of nonphosphorylated neurofilaments. Brain Research, 2022, 1777, 147767.	2.2	2
741	Deep residual inception encoderâ€decoder network for amyloid PET harmonization. Alzheimer's and Dementia, 2022, 18, 2448-2457.	0.8	10
742	Nano-based phytodrug delivery systems for the management of neurodegenerative disorders. , 2022, , 207-222.		0
743	Human APOE É›3 and APOE É›4 Alleles Have Differential Effects on Mouse Olfactory Epithelium. Journal of Alzheimer's Disease, 2022, 85, 1481-1494.	2.6	3
744	Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimerâ€™s Disease Neuropathology. Journal of Alzheimer's Disease, 2022, 87, 51-81.	2.6	14
746	Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathologica, 1994, 87, 174-186.	7.7	4
747	Alzheimer's disease with asymmetric atrophy of the cerebral hemispheres: morphometric analysis of four cases. Acta Neuropathologica, 1994, 88, 440-447.	7.7	0
748	Neurogenesis in aging and age-related neurodegenerative diseases. Ageing Research Reviews, 2022, 78, 101636.	10.9	41
749	Genotypeâ€"phenotype correlation of T-cell subtypes reveals senescent and cytotoxic genes in Alzheimerâ€™s disease. Human Molecular Genetics, 2022, 31, 3355-3366.	2.9	2
750	Noradrenergic Modulation of the Piriform Cortex: A Possible Avenue for Understanding Pre-Clinical Alzheimerâ€™s Disease Pathogenesis. Frontiers in Cellular Neuroscience, 0, 16, .	3.7	1
751	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. Journal of Neuropathology and Experimental Neurology, 2022, 81, 387-413.	1.7	6

#	Article	IF	Citations
753	Olfactory acuity and cognitive function converge in older adulthood: Support for the common cause hypothesis.. Psychology and Aging, 2002, 17, 392-404.	1.6	9
754	Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites. Frontiers in Neuroscience, 0, 16, .	2.8	10
755	Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-Î² and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia. JAMA Neurology, 2022, 79, 710.	9.0	10
756	Evaluating measurement properties of subjective cognitive decline self-reported outcome measures: a systematic review. Systematic Reviews, 2022, 11, .	5.3	7
757	Neuropathology and cholinesterase expression in the brains of octogenarians and older. Chemico-Biological Interactions, 2022, 364, 110065.	4.0	3
758	Molecular linkages among AÎ², tau, impaired mitophagy, and mitochondrial dysfunction in Alzheimerâ€™s disease. , 2022, , 91-109.		0
759	Hypothesis review: Alzheimer's overture guidelines. Brain Pathology, 2023, 33, .	4.1	18
760	Pattern of structural magnetic resonance imaging lesions in the patients with progressive cognitive decline: A single-center study in Southeast Nigeria. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2022, 29, 59.	0.1	1
762	Association of apolipoprotein E epsilon 4 and cognitive impairment in adults living with human immunodeficiency virus: a meta-analysis. Chinese Medical Journal, 2022, 135, 2677-2686.	2.3	0
764	A Survey of Deep Learning for Alzheimerâ€™s Disease. Machine Learning and Knowledge Extraction, 2023, 5, 611-668.	5.0	6
765	Chronic traumatic encephalopathy neuropathologic change is uncommon in men who played amateur American football. Frontiers in Neurology, 0, 14, .	2.4	1
766	Microvascular Contributions to Alzheimer Disease Pathogenesis: Is Alzheimer Disease Primarily an Endotheliopathy?. Biomolecules, 2023, 13, 830.	4.0	1
767	Morphometric analysis of medial temporal lobe subregions in Alzheimer's disease using high-resolution MRI. Brain Structure and Function, 0, , .	2.3	0
768	Nicotinic Acetylcholine Receptor Dysfunction in Addiction and in Some Neurodegenerative and Neuropsychiatric Diseases. Cells, 2023, 12, 2051.	4.1	1
769	Multi-domain Cognitive Testing: A Biomarker for Classifying the Cognitive Status of Mild Cognitive Impairment and Alzheimer's Disease. Neurology India, 2022, 70, 1057.	0.4	2
770	Design, in Silico Studies and Biological Evaluation of New Chiral Thiourea and 1,3â€Thiazolidineâ€4,5â€dione Derivatives. Chemistry and Biodiversity, 2023, 20, .	2.1	1
771	Implication of the cooking oil-peroxidation product â€œhydroxynonenalâ€•for Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	3
772	Transmembrane protein 184B (TMEM184B) promotes expression of synaptic gene networks in the mouse hippocampus. BMC Genomics, 2023, 24, .	2.8	0

#	Article	IF	Citations
773	Senile plaques and phosphorylated tau deposition in a super-aged rhesus monkey (<i>Macaca) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.9	0
774	Amyloid induced hyperexcitability in default mode network drives medial temporal hyperactivity and early tau accumulation. Neuron, 2024, 112, 676-686.e4.	8.1	3
775	Amidst an amygdala renaissance in Alzheimerâ€™s disease. Brain, 2024, 147, 816-829.	7.6	1
776	Antibodies Raised Against an AÎ² Oligomer Mimic Recognize Pathological Features in Alzheimerâ€™s Disease and Associated Amyloid-Disease Brain Tissue. ACS Central Science, 0, , .	11.3	0
777	Akt activation ameliorates deficits in hippocampal-dependent memory and activity-dependent synaptic protein synthesis in an Alzheimerâ€™s disease mouse model. Journal of Biological Chemistry, 2024, 300, 105619.	3.4	0
778	Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History. Journal of Clinical Medicine, 2024, 13, 536.	2.4	0
779	Human iPSC-derived retinal organoids develop robust Alzheimerâ€™s disease neuropathology. Frontiers in Cellular Neuroscience, 0, 18, .	3.7	0
780	Multiple Early Biomarkers to Predict Cognitive Decline in Dementia-Free Older Adults. Journal of Geriatric Psychiatry and Neurology, 0, , .	2.3	0
781	Neurotoxic Microglial Activation via IFNÎ³â€Induced Nrf2 Reduction Exacerbating Alzheimer's Disease. Advanced Science, 0, , .	11.2	0